Document:

Adamis Pharmaceuticals, Corporation 10-Q

     

 Exhibit 10.3

 

*** Certain identified information has
been omitted from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant
if publicly disclosed. Such omitted information is indicated by brackets (“[...***...]” in this exhibit.
***

 

LICENSE
AGREEMENT

 

This License Agreement (“Agreement”) is entered
into by and between Matrix Biomed, Inc. (“Licensor”), a Delaware corporation having a place of business at 2301
Dupont Drive, Suite 420, Irvine, California 92612, and Adamis Pharmaceuticals (“Licensee”), a Delaware corporation
having a principal place of business at 11682 El Camino Real, Suite 300, San Diego, California 92130. Licensor and Licensee may
be referred to herein individually as a “Party” or collectively as the “Parties”.

 

RECITALS

 

A.            Licensor
has built a portfolio of intellectual property for the use of the drug Tempol for [***] (“Tempol”) in various.

 

B.            Licensor
will license patents and know-how that relate to using the drug Tempol for COVID-19 infection, respiratory syncytial virus infection,
influenza infection, and asthma, as well as a therapeutic for radiation-induced dermatitis.

 

C.            Licensee
is a specialty biopharmaceutical company focused on developing and commercializing pharmaceutical products.

 

D.            Licensee
wishes to acquire a world-wide, exclusive*, license to the Licensed Patents and Related Know How (as defined below) solely for
the purpose of developing, producing and selling Licensed Products within the Licensed Field of Use (as defined below).

 

NOW THEREFORE, for good and valuable consideration,
the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:

 

1.            Definitions.
As used in this Agreement, the following terms shall have the meanings set forth below:

 

		1.1	“Affiliate” means any person or entity that owns or controls, is owned or controlled by, or is under common control
with the Licensee, where, for purposes of this definition, the term “control” means the possession, direct or indirect,
or the powers to direct or cause the direction of the management and policies of an entity, whether through ownership of voting
securities, by contract or otherwise.

 

		1.2	“Claim” shall, unless otherwise specified, mean an issued claim in any of the patents licensed hereunder which
read on the Licensed Product, which claim has not lapsed, been disclaimed, cancelled or become abandoned and which claim has not
been declared invalid or unenforceable by a final decision of a court of competent jurisdiction or other appropriate body of competent
jurisdiction and which decision is not subject to appeal or reversal by a higher court or body.

  

    1 

     

    

 

		1.3	“Confidential Information” means all information concerning the business and proprietary affairs of a Party which
a reasonable person would understand to be confidential, including, without limitation, product specifications, data, know-how,
formulae, compositions, processes, designs, sketches, photographs, graphs, drawings, samples, inventions and ideas, past, current,
and planned research and development, current and planned manufacturing or distribution methods and processes, market studies,
business plans, computer software and programs (including object code and source code), computer software and database technologies,
systems, structures and architectures (and related processes, formulae, composition, devices, inventions, discoveries, concepts,
ideas, designs, methods and information); provided, however, that Confidential Information shall not include (a) information that
is in the public domain at the time it is disclosed to a receiving Party or enters the public domain through no fault of a receiving
Party; (b) information lawfully obtained by a receiving Party from a third party not in breach of any obligation of confidentiality
or non-use to a disclosing Party; (c) information already known to a receiving Party at the time of disclosure by a disclosing
Party as shown by contemporaneous documentation acknowledging same; and (d) information furnished to others by a Party intended
not to have restriction on disclosure.

 

		1.4	“Effective Date” means the date this Agreement has been signed by all Parties hereto.

 

		1.5	“IND” means Investigational New Drug application relating to the use of Tempol in the Licensed Field of Use that
is owned or controlled by Licensor.

 

		1.6	“Insolvent” and “Insolvency” means the inability of a person to pay their debts as such debts become
due in the ordinary course of business.

 

		1.7	“Licensed Field of Use” means the use of the drug Tempol for COVID-19 infection, respiratory syncytial virus infection,
and influenza infection, asthma, as well as a therapeutic for radiation-induced dermatitis.

 

		1.8	“Licensed Patent(s)” means (i) the patent and patent application listed on Exhibit A, hereto, for using
the drug Tempol for the License Field of Use, as defined in Section 1.7; and (ii) any patents licensed from [***] pursuant to [***]
attached hereto as Exhibit
B, for [***].

 

		1.9	“Licensed Product(s)” shall mean any product, device, system, apparatus, kit, component, method, procedure, application,
process or service the manufacture, use, sale, offer for sale, commercialization, exploitation, disposition, practice or import
which is the subject of the licenses granted in this Agreement within the Licensed Field of Use or utilizes the Related Know How.

 

		1.10	“Licensed Territory” means the world.

 

    2 

     

    

 

		1.11	“Net Sales” means the gross invoice sales price or other gross consideration received from the Sale of Licensed
Products by Licensee, less (a) sales, transfer, and all other taxes or excises; (b) returns and refunds; (c) discounts, allowances
and/or rebates; and (d) commissions paid to selling agents. For clarity, Net Sales does not include Licensed Products that are
Otherwise Disposed Of.

 

		1.12	“Non-affiliate” shall mean any person or entity that is not otherwise the Licensee or an Affiliate.

 

		1.13	“Otherwise Disposed Of” means not Sold, but delivered to others without receipt of any consideration such as when
product is distributed for use in research, product development, clinical or other experimental non-commercial trials.

 

		1.14	“Prosecution Matters” mean those steps taken in an effort to have a patent registration issued by the relevant
registration authority, including, without limitation, the drafting and filing of the initial application and the drafting and
filing of any responses to office actions or other communications from the relevant registration authority.

 

		1.15	“Regulatory Body” means a governmental body such as the United States Food and Drug Administration or other legally-recognized
entity that must approve or otherwise license the manufacture, use, testing or sale of a Licensed Product in any jurisdiction in
the Licensed Territory.

 

		1.16	“Related Know How” shall mean Licensor’s unpatented know how, technical data, Trade Secrets, or other information
of any kind, owned or licensed by Licensor, which is directly within the Licensed Field of Use, but which is not the subject of
an issued patent within the Licensed Patents.

 

		1.17	“Sale” or “Sold” means to sell or lease for consideration Licensed Products.

 

		1.18	“Tempol” means [***].

 

		1.19	“Trade Secrets” means data, formulae, compositions, processes, graphs, samples, forms, inventions and ideas, existing
vendor and supplier lists or prospective vendor and supplier lists, pricing and cost data, market studies, business plans, computer
software and programs (including object code and source code), database technologies, systems, structures and architectures (and
related processes, formulae, composition, improvements, devices, inventions, discoveries, concepts, ideas, designs, methods and
information), and any other information, however documented.

 

2.            Term and Termination.

 

		2.1	Term. This Agreement shall become effective as of the Effective Date. Unless terminated earlier in accordance with this
Section 2, this Agreement shall terminate on the expiration of the last to expire of the patents licensed herein, or if later on
the abandonment of the last to be abandoned patent application licensed herein (such period of time from the Effective Date until
the date of termination being referred to herein as the “Term”).
For the purpose of this Agreement, “abandonment” is defined with reference to 37 C.F.R. Sections 1.135, 1.138 or any
applicable equivalent foreign patent provisions.

 

    3 

     

    

 

		2.2	Termination by Licensor. In addition to its rights to enforce the provisions of any other Section of this Agreement,
Licensor shall have the right, at its option, to terminate this Agreement, in accordance with the procedures set forth in Section
2.5, on the occurrence of any one or more of the following events after delivery to Licensee of a written notice specifying such
event and the passage of the applicable cure periods specified herein or in the absence of specified cure periods, the failure
to remedy such breach within [***] of notice thereof:

 

		2.2.1	On the material breach of or default of this Agreement by Licensee; or

 

		2.2.2	If Licensee fails to [***].

 

		2.2.3	For purposes of Section 2.2.1, a material breach or default of this Agreement shall include, but not be limited to, each of
the following: (i) Licensee attempts to [***]; (ii) or failure by Licensee to [***].

 

		2.3	Termination by Licensee.

 

		2.3.1	In addition to its rights to enforce the provisions of any other Section of this Agreement, Licensee shall have the right,
at its option, to terminate this Agreement, in accordance with the procedures set forth in Section 2.5, on Licensor’s material
breach and Licensor’s failure to remedy any such material breach within [***] after written notice thereof by Licensee.

 

		2.3.2	In addition, without limiting the forgoing and notwithstanding anything to the contrary, including Section 2.5 below, Licensee
may within its sole discretion terminate this Agreement at any time without cause or for its own convenience upon providing [***]
written notice to Licensor. Upon such a termination for convenience or without default, the Licensee may cease the payment of any
future payments or fees under this Agreement; provided, however, that Licensee shall remain liable for any pre-termination obligations
under this Agreement.

 

		2.4	Termination Upon Licensee Failing to [***]. Licensee hereby covenants and agrees that it shall [***]. In the event of
any breach under this Section 2.4 [***] provided, however, that Licensee shall remain liable for any pre-termination obligations
under this Agreement.

 

    4 

     

    

 

		2.5	Exercise of Rights by Terminating Party. With the exception for Section 2.4 herein, the Party terminating this Agreement
(the “Terminating Party”) may exercise its right of termination, only after giving all notices described herein
and the expiration of all cure periods, if any, by giving the other Party, or its trustees, receivers or assigns, as the case may
be (the “Non-Terminating
Party”), [***] prior written notice of such Terminating Party’s election to terminate (unless a shorter
or longer period is specified in a provision of this Agreement). Such notice shall include a brief description of the basis for
such termination, but any inadequacy in the description claimed by the Non-Terminating Party will not be cause to deny a termination.
On expiration of such period, this Agreement shall automatically terminate, unless the Non-Terminating Party has elected to pursue
the resolution of any controversy in accordance with Section 11 hereof within the applicable cure period, in which event the question
of whether the Terminating Party is entitled to terminate this Agreement shall be determined by the dispute resolution process
as provided in Section 11 and this Agreement shall not be terminated by the Terminating Party until such process has finally determined
that the Terminating Party is entitled to terminate this Agreement.

 

		2.6	Effect of Termination. Upon termination of this Agreement by either Party or due the expiration of the Term, all license
rights granted hereunder will terminate and all rights to use the drug Tempol in the Licensed Field of Use will revert back to
Licensor.

 

3.            Licenses.

 

		3.1	License Grants. Subject to the terms and conditions of this Agreement, Licensor hereby grants to Licensee, an exclusive*
royalty-free license under the Licensed Patents and Related Know-How, solely within the Licensed Field of Use, in order to make,
have made, use, offer to sell, sell, import, manufacture, practice and otherwise exploit, dispose of and commercialize the Licensed
Products solely within the Licensed Field of Use in the Licensed Territory.

 

Licensor will solely own any and all patents and patent
applications related to Tempol that are now existing or derived from work under this Agreement. Subject to the terms and conditions
of this Agreement, Licensor hereby grants to Licensee, an exclusive royalty-free license to any patent and patent applications
derived from work under this Agreement and an exclusive royalty-free license in the Related Know-How to the extent not otherwise
within the scope of the exclusive grant to the patent and patent applications derived from work under this Agreement, in order
to make, have made, use, offer to sell, sell, import, manufacture, practice and otherwise exploit, dispose of and commercialize
the Licensed Products solely within the Licensed Field of Use in the Licensed Territory.

 

*As used herein “exclusive” excludes [***].

 

		3.2	Sublicensing. The Licensee may not sublicense the license it is granted hereunder without the express written consent
of the Licensor, which may be withheld or granted in its sole discretion. Any sublicense of this license granted hereunder must
be pursuant to a separate written agreement signed by both the Licensor and the Licensee.

 

    5 

     

    

 

4.            Initial Obligations
of the Parties.

 

		4.1	Licensee.

 

		4.1.1	Cash License Fee. In consideration for this license Licensee shall pay Licensor a onetime, non-refundable upfront payment
(the “Cash License Fee”) of Two Hundred Fifty Thousand U.S. Dollars ($250,000.00) payable upon execution of
this Agreement by both Parties. The date Licensor receives the Cash License Fee is the “Effective Date”. The
Cash License Fee is not refundable, not creditable, and not an advance against any fees, royalties, or other monies required to
be paid under the terms of this Agreement.

 

		4.1.2	Stock License Fee. On the Effective Date Adamis will issue Matrix One Million (1,000,000) shares of its Series B Convertible
Preferred Stock, with standard restrictive legends (the “Stock Fee”). The rights and preferences of the Series
B Preferred Stock are set forth on Exhibit C, and such shares will be converted into shares of Adamis common stock. The Company
will make all reasonable efforts necessary to ensure a Capital Event occurs no later than [***].

 

The Stock Fee is not refundable, not creditable, and
not an advance any fees, royalties, or other monies required to be paid to Matrix under the terms of this Agreement.

 

		4.1.3	Payment of Expenses by Licensee. Licensee will be responsible for funding the preclinical and clinical development related
to the use of the drug Tempol for the Licensed Field of Use under the license granted by this Agreement (the “Company
Expenses”).

 

		4.2	Licensor. Within [***] of receipt of the License Fee; Licensor shall provide the Licensee with Good Manufacturing Practice
(GMP) Tempol for preclinical and/or clinical studies within the Field of Use. The Licensee will have immediate access to the information
in the IND and all required regulatory documents within the Field of Use and will be able to reference all such filings and materials
and any data referenced therein.

 

Licensee will purchase GMP-grade Tempol necessary for
any preclinical or clinical work, as well as for any use in any Licensed Products, exclusively from the Licensor. The cost of the
drug will be [***]. If Licensor becomes unable to provide GMP grade Tempol to Licensee for any purpose under this Agreement or
licensee can produce Tempol more cost effectively, then Licensee has the right to manufacture, or have manufactured, GMP grade
Tempol using a third party of their choosing. In the event Licensee is required to use a third-party manufacturer for GMP-grade
Tempol under this Section, then Licensor agrees to provide Licensee with any know-how, trade secrets or other technical assistance
required or useful to manufacture GMP grade Tempol.

 

    6 

     

    

 

Licensor will transfer for Licensee’s future clinical
trials for [***] for [***] patients [***], enough GMP-grade Tempol to conduct a clinical trial for [***], at a total cost of [***]
to be paid by Licensee [***].

 

5.             Government Approvals;
Conduct of Studies. Except as set forth in Section 6 herein, Licensee will be responsible for the filings, costs and other
matters related to establishing compliance of the Licensed Products with all current and future laws, statutes, rules and regulations
of any Regulatory Body. Without limiting the generality of the foregoing, all studies, research and testing done by or on behalf
of Licensee or Licensor, its Affiliates under this Agreement shall be performed in compliance with any applicable federal, state
or local laws, rules, policies and regulations governing the conduct of the studies, research and testing.

 

6.             Joint Research
and Development Steering Committee. Licensor and Licensee shall form a Steering Committee that will meet and confer regularly,
but no less than [***], to discuss technical, regulatory, clinical and business issues related to the development, testing and
approval of Licensed Products. The Licensor and Licensee shall each appoint [***].

 

At each Steering Committee meeting the participants shall review
[***]. All material decisions related to the testing and development of a Licensed Product under the terms of this Agreement must
be approved by [***] including, but not limited to, decisions related to [***]. Meetings can be held in person, telephonically
or by teleconference; meeting notices must be given no less than [***] in advance. At least [***] Steering Committee members must
be present for a quorum to exist, however, all votes taken when less than all members are present must be [***].

 

As part of the expenses related to the development of the drug
Tempol within the Licensed Field of Use, all members of the Steering Committee will receive compensation for all travel expenses.

 

7.             Prosecution,
Infringement and Enforcement.

 

		7.1	Prosecution and Maintenance of Licensed Patents in the United States. Licensor shall have the sole right to file, prosecute
and maintain all Licensed Patents and Licensor Patents and patent applications for Licensed Patents and Licensor Derived Patents
in the United States and worldwide.

 

		7.2	Infringement and Enforcement Actions.

 

		7.2.1	Each Party shall notify the other Party of any suspected infringement(s) of the patents licensed hereunder or Related Know-How
and shall inform the other Party of any evidence of such infringement(s).

 

		7.2.2	[***] shall control any litigation, claim, action or proceeding it initiates, including the selection of counsel. [***] may
retain additional counsel of its own selection and at its own expense to observe the litigation and to advise or assist [***].
[***] and its counsel will cooperate with and seek the input of [***] in such matters.

 

    7 

     

    

 

		7.2.3	[***] may settle with an infringer without the prior approval of [***] (with such approval not to be unreasonably withheld
or delayed) if such settlement would prejudice the rights of [***].

 

		7.2.4	Each Party will provide the other with reasonable cooperation in any and all litigation matters or other claim, action or proceedings
arising from or relating to the licensed and licensable patents and Related Know How subject to this Agreement.

 

8.       Confidentiality.

 

		8.1	Protected Information. Each Party shall regard and preserve as confidential all Trade Secrets and other Confidential
Information pertaining to the other Party that has been or may be obtained by a Party by reason of this Agreement. Except in accordance
with this Agreement, a Party shall not disclose, use for its own benefit or purpose, deliver, reproduce or in any way allow any
Trade Secrets or Confidential Information to be delivered to, or used by, any third party without the specific written direction
or written consent of a duly authorized representative of the disclosing Party. During or after the termination of this Agreement,
no Party shall publish, release or otherwise make available to any third party any information describing any Trade Secret, or
for a period of [***] other Confidential Information without prior specific written authorization of the Disclosing Party. Except
as required by this Agreement, a Party shall not appropriate, retain or copy any Confidential Information or Trade Secrets of another
Party.

 

		8.2	Compelled Disclosure. In the event a receiving Party is required by legal process or applicable law (such as the Federal
or California’s Freedom of Information Acts or other similar “sunshine” acts or provisions) to disclose such
Trade Secrets or Confidential Information, a receiving Party shall provide the disclosing Party with prompt notice of such request
or requirement in order to enable the disclosing Party (a) to seek an appropriate protective or other remedy; or (b) to consult
with the receiving Party with respect to the disclosing Party’s taking steps to resist or narrow the scope of such request
or legal process. The receiving Party that is subject to the disclosure request or requirement shall always seek to disclose only
that portion of the disclosed information that is legally required to be disclosed.

 

9.       Royalty Payments.

 

		9.1	Minimum Annual Royalty Payment. There is no minimum annual royalty or other minimum annual payment due Licensor by Licensee
under this Agreement.

 

		9.2	Profit Sharing. The Parties shall divide Profits from the sales of Licensed Products(s) equally. As used herein Profit
is defined as Net Sales less reasonable costs incurred by Licensee for manufacturing, marketing and distribution of Licensed Products,
either directly or through an intermediary. [***] expenses shall include, but are not limited to the costs for [***]. Payments
to the Licensor shall be made quarterly beginning [***] and shall include [***].

 

    8 

     

    

 

		9.3	Books and Records. The Licensee will keep books and records accurately showing all payments due the Licensor and all
Licensed Products developed, manufactured, used, offered for Sale, imported, Sold, and/or otherwise exploited under the terms of
this Agreement, and provide such reports to the Licensor quarterly. The books and records will also include detailed entries for
[***] incurred by [***], with sufficient detail to ensure all [***] were directly related [***]. Such books and records will be
preserved for at least [***] after the date of the payment to which they pertain and will be open to examination by representatives
or agents of the Licensor during regular business hours to determine their accuracy and assess the Licensee’s compliance
with the terms of this Agreement. The fees and expenses of performing the examination will be paid by the Licensor. If, however,
an error in Profits of more than [***] of [***] is discovered or any other material term of this Agreement is discovered to have
been breached, the Licensee shall bear the cost of the examination. The Licensee shall remit any underpayment to the Licensor within
[***] days of the examination results; likewise, the Licensor shall remit any overpayments to Licensee within [***] of the examination
results.

 

10.           Mutual Indemnification.
Licensee and Licensor shall indemnify and hold each other and its officers, directors, agents and employees harmless from and against
any and all costs, expenses, settlements and judgments, including reasonable attorneys’ fees, and costs and expenses incidental
thereto (an “Action”)
which may be suffered by, accrued against, charged to or recoverable from the indemnified party or any of its officers, directors,
agents or employees, arising out of any personal injuries, death or tangible property damage liability claim related to the manufacture,
distribution or use of any Licensed Product or the practicing of the Licensed Patents, except to the extent such claim arises out
of a breach of this Agreement by each Party or out of the gross negligence or willful misconduct of each Party, its officers, directors,
employees or agents.

 

11.           Dispute Resolution.

 

		11.1	Negotiation. In the event of any dispute arising out of or in connection with this Agreement, as a condition precedent
to any further action brought by either Licensor or Licensee against the other, the aggrieved party (“Aggrieved Party”)
shall give the other party (the “Non-Aggrieved Party”) written notice of the matter which the Aggrieved Party
considers to be in dispute. The notice will describe the issue in dispute in reasonable detail to apprise the Non-Aggrieved Party
about the issue in dispute. Within [***] of the receipt of the notice (“Notice Date”) delivered in accordance
with the notice provisions of this Agreement, Chief Executive Officer of Licensor and the Chief Executive Officer of Licensee will
meet (either telephonically or in person) in an attempt to resolve the dispute. The parties to this Agreement agree that they will
make reasonable effort to resolve the dispute within [***] of the Notice Date so as to avoid arbitration as herein provided. If
the dispute is not fully settled by negotiation among the parties as provided in this section within [***], then the condition
precedent to arbitration shall be deemed satisfied and the dispute (to the extent not resolved) may be submitted to arbitration
as herein provided. For clarity, any documents, discussions and partial settlements exchanged or agreed upon in the negotiations
for settlement of the dispute may be admitted or provided to the arbitrators as evidence or statement of facts and position in
any arbitration.

 

    9 

     

    

 

		11.2	Arbitration. This Agreement shall be governed by and construed in accordance with the laws of the State of California,
without regard to the application of principles of conflicts of law. Any disputes between the parties relating to this Agreement
shall be resolved by binding arbitration before the American Arbitration Association in Los Angeles pursuant to its Commercial
Arbitration Rules, then in effect.

 

Notwithstanding anything to the contrary in the Rules,
the Licensee and Licensor agree that the place of arbitration will be in the Los Angeles County, California and each waives any
objection to that venue for the arbitration for any action that arises out of the arbitration. The choice of law used in the interpretation
of this Agreement shall be governed by the general laws of the United States with respect to any intellectual property issues and
any other issues under this Agreement and, to the extent that such United States law is not clearly defined or is not applicable,
then by the laws of the State of California.

 

12.           Export Controls.
Licensor and Licensee will each comply with all applicable United States or foreign export or import laws and regulations in connection
with the licensing of any of the patents and patentable technology and Related Know How, Sale of the Licensed Products or sub-license
of any technology or technical data relating to the Licensed Products.

 

13.           Assignment.
This Agreement, including its rights and obligations, may not be assigned by a Party without the prior written consent of the Licensor,
which consent will be in the sole discretion of Licensor. Notwithstanding the foregoing prohibition, Licensee may, without the
consent of Licensor, merge into, consolidate with, or transfer substantially all of its assets, business or stock to any entity,
so long as the successor-surviving entity in any such merger, consolidation, reorganization or transfer, assumes in writing the
Licensee’s obligations of this Agreement. Such merger, consolidation, reorganization or transfer shall not constitute a breach
of this Article or default under this Agreement.

 

14.           Miscellaneous.

 

		14.1	Severability. The Parties agree that if any part, term, or provision of this Agreement shall be found illegal or in
conflict with any valid controlling law, the validity of the remaining provisions shall not be affected thereby.

 

		14.2	Survival. Sections 2, 8, 9, 10, 11 and 14 shall survive expiration or termination of this Agreement.

 

    10 

     

    

 

		14.3	Notices. All notices under this Agreement shall be deemed to have been fully given when done in writing, with reference
to this Agreement, and when (a) delivered personally; (b) five (5) days after having been sent by United States mail, registered
or certified, return receipt requested, postage prepaid; or (c) one (1) day after deposit with a nationally recognized commercial
overnight carrier, with written verification of receipt. Communications or notices by other means such as e-mail shall only be
effective when received and the sending or notifying party shall have the burden of proving receipt of such communication. All
communications will be sent to the addresses or facsimile numbers set forth below or to such other address as may be designated
by a Party by giving written notice to the other Party.

 

	If
    to Licensor:	Matrix Biomed, Inc.
	 	2301 Dupont Drive
	 	Irvine, CA 92612
	 	Tel:	[***]
	 	E-mail:	[***]
	 	 	 
	with
    a copy to (which shall not constitute notice hereunder):
	 	 	 
	 	[***]	 
	 	Attn: [***]	 
	 	Fax:	[***]
	 	E-mail:	[***]
	 	 	 
	If
    to Licensee:	Adamis Pharmaceuticals, Inc.
	 	11682 El Camino Real, Suite 300
	 	San Diego, CA 92130
	 	Attn: Dr. Dennis J. Carlo, President
	 	Tel:	(858) 997-2400
	 	E-mail:	[***]
	 	 	 
	with
    a copy to (which shall not constitute notice hereunder):
	 
	 	[***]	 
	 	Attn: [***]	 
	 	Fax:	[***]
	 	E-mail:	[***]

  

		14.4	Public Statements. Neither Party will issue any news release, publicity, advertising or other form of public announcement
relating to this Agreement without the prior written approval of the other Parties which approval shall not be unreasonably withheld
or delayed. Notwithstanding the foregoing, Licensee may make any required public announcement without the prior written approval
of any other Party which relates to its business, the terms of this Agreement, and the patents and Related Know How subject to
this Agreement as required by law or determined to be in the best interests of the Licensee to comply with any and all disclosure
laws applicable to the Licensee.

 

    11 

     

    

 

		14.5	Entire Agreement, Amendment. This Agreement, along with the referenced Research Agreement and other agreements referred
to herein, represents the entire understanding between the Parties, and supersedes all other agreements, express or implied, among
the Parties concerning the subject matter hereof. A provision of this Agreement may be altered or amended only by a writing signed
by the Parties.

 

		14.6	Waiver. No waiver by a Party of any breach of this Agreement, no matter how long continuing or how often repeated, shall
be deemed a waiver of any subsequent breach thereof, nor shall any delay or omission on the part of a Party to exercise any right,
power, or privilege hereunder be deemed a waiver of such right, power or privilege.

 

		14.7	No Agency. The relationship among the Parties is that of independent contractors. Except as otherwise stated herein,
neither Party shall be deemed to be an agent of the other in connection with the exercise of any rights hereunder, and neither
shall have any right or authority to assume or create any obligation or responsibility on behalf of the other.

 

		14.8	Construction. This Agreement shall not be construed more strictly against a Party than any other by virtue of the fact
that it may have been prepared by counsel for one of the Parties, it being recognized that all Parties have contributed substantially
and materially to the preparation of this Agreement.

 

		14.9	Counterparts. This Agreement may be executed simultaneously in more than one (1) counterpart, and each of which shall
be deemed an original, but all of which together shall constitute one (1) and the same instrument. The Agreement will be considered
executed when original signatures have been exchanged or when signatures have been exchanged via facsimile or electronic transmission,
including, without limitation, signatures delivered in portable document format (.pdf).

 

		14.10	Headings. The headings of the several sections are inserted for convenience of reference only and are not intended to
be a part of or to affect the meaning or interpretation of this Agreement.

  

[SIGNATURES ON FOLLOWING PAGE]

 

    12 

     

    

 

IN WITNESS WHEREOF, the parties have executed this License Agreement
effective as of the day and year first above written.

 

	 	“LICENSOR”
	 	 	 
	 	Matrix Biomed, Inc.
	 	a Delaware corporation
	 	 	 
	 	By:	/s/ Allyn Burroughs
	 	 	Allyn Burroughs, Chairman
	 	 	 
	 	“LICENSEE”
	 	 	 
	 	Adamis Pharmaceuticals, Inc.
	 	a Delaware corporation
	 	 	 
	 	By:	/s/ Dennis J. Carlo
	 	 	Dennis J. Carlo, CEO and President

 

[SIGNATURE
PAGE TO LICENSE AGREEMENT]

 

     

     

    

 

EXHIBIT A

 

TEMPOL PATENT AND PATENT APPLICATION

 

[***]Adamis Pharmaceuticals Corporation 10-Q

     

Exhibit 10.6

 

*** Certain identified information has
been omitted from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant
if publicly disclosed. Such omitted information is indicated by brackets (“[...***...]” in this exhibit.
***

 

DISTRIBUTION AND COMMERCIALIZATION
AGREEMENT

 

This Distribution and
Commercialization Agreement (the “Agreement”) is made effective as of the Effective Date (as defined herein)
by and between Adamis Pharmaceuticals Corporation, a corporation organized under the laws of Delaware, with an office located at
11682 El Camino Real, Suite #300, San Diego, California 92130 (“Company”) and USWM, LLC, a limited liability
company organized under the laws of Delaware, with an office at [***] (“USWM”). Company and USWM may hereafter
be referred to collectively as the “Parties” and individually as a “Party”.

 

WHEREAS, Company,
pursuant to the terms of this Agreement, would like to manufacture and supply Products (as defined below) to USWM for distribution
and commercialization in the Territory (as defined below); and

 

WHEREAS, USWM,
pursuant to the terms of this Agreement, would like to purchase the Products from Company for distribution and commercialization
in the Territory.

 

NOW, THEREFORE,
in consideration of the mutual promises, covenants and agreements hereinafter set forth, the Parties hereto, intending to be legally
bound, hereby agree as follows:

 

1.       
    DEFINITIONS. In this Agreement, the following words shall have the following
meanings:

 

1.1.          “Act”
means the Federal Food, Drug and Cosmetic Act of 1938, including any amendments thereto and all regulations promulgated thereunder
or under any similar act or set of laws in the Territory.

 

1.2.          “Accrued
Losses” means, for any particular Calendar Quarter(s) occurring after the quarter in which Profitability has been reached,
the amount by which the calculation of “Net Profit” for the Calendar Quarter (or Calendar Quarters, if and to the extent
there are Accrued Losses in more than one (1) Calendar Quarter) is less than zero dollars ($0.00).

 

1.3.          “Additional
Costs” means, for any applicable Calendar Quarter, the total costs, inclusive of (i) [***], (ii) [***], (iii) [***],
and (iv) [***]; in each case, only to the extent not overlapping with any amount deducted in the calculation of Net Sales.

 

1.4.          “Affiliate”
means, with respect to any Person, any Person which, directly or indirectly, controls, is controlled by, or is under common control
with, the specified Person, but only for the period of time the Person first identified in this Section 1.3 controls, is controlled
by, or is under common control, with the respective specified Person. For the purposes of this definition, the term “control,”
as applied to any Person, means the possession, directly or indirectly, of the power to direct or cause the direction of the management
of that Person, whether through ownership of more than fifty percent (50%) voting securities or otherwise.

 

    	Page 1
	 

     

    

 

 

1.5.          “API”
means the compound epinephrine and/or naloxone, as applicable, and as further described in the Specifications.

 

1.6.          “Applicable
Laws” means all laws, ordinances, rules and regulations applicable to the Parties’ activities under this Agreement,
including, without limitation, the Manufacture, Development, or Processing of API or Product, and the obligations of each Party
as the context requires, including, without limitation: (i) all applicable federal, state and local laws and regulations of the
Territory; (ii) the Act; and (iii) cGMP.

 

1.7.          “Bankruptcy
Code” means the United States Bankruptcy Code (Title 11 of the United States Code).

 

1.8.          “Batch”
means a specific quantity of the Product that is intended to have uniform character and quality within specified limits, and is
produced according to a single Manufacturing order during the same cycle of Manufacture.

 

1.9.          “Batch
Record” means Batch production and control records as set forth in 21 C.F.R. § 211.188, as may be amended from time-to-time.

 

1.10.        “Books
and Records” means the books and records maintained by the Parties relating to the Products in the Territory and/or the
obligations hereunder in sufficient detail, in accordance with GAAP (to the extent applicable) and in accordance with the terms
of this Agreement.

 

1.11.        “Business”
means, whether by Company or a Third Party, the development, sale, marketing, manufacturing, distribution and commercialization
of the Products.

 

1.12.        “Business
Day” means any day that is not a Saturday, Sunday or other day on which commercial banks located in New York, New York
are authorized or required to be closed, as the case may be.

 

1.13.        “Calendar
Quarter” means any of the three-month periods beginning January 1, April 1, July 1 or October 1 of any calendar year.

 

1.14.        “Certificate
of Analysis” “Certificate of Compliance” and “Certificate of Release” (collectively the
“Certificates”) means a document or documents signed and dated by a duly authorized representative of Company
certifying that the Product Conforms to the Specifications as set forth in the Quality Agreement and/or was prepared in compliance
with cGMP, and in accordance with Section 3.11.1.

 

1.15.        “cGMP”
or “Good Manufacturing Practices” means current good manufacturing practices as set forth in 21 C.F.R. Parts
210 and 211, as established by the FDA or any similar set of laws, regulations, rules, or practices in the Territory or otherwise
applicable to Development, Manufacture, Processing or supply of Product pursuant to this Agreement, as may be amended from time-to-time.

 

    	Page 2
	 

     

    

 

 

1.16.        “Claim”
means any claim, action, suit, demand or other legal assertion or proceeding brought by a Third Party against any of the USWM Indemnified
Parties and/or Company Indemnified Parties, as the case may be, related to any Liability.

 

1.17.        “Commercialize”
or “Commercialization” means the activities for general management, legal, compliance, finance, regulatory,
quality, medical affairs, marketing, sales, sales management, pricing, promotion, and distribution of the Products.

 

1.18.        “Commercially
Reasonable Efforts” means, with respect to the efforts to be expended by a Party with respect to any objective under
this Agreement, reasonable, diligent, good-faith efforts to accomplish such objective as such Party would normally use to accomplish
a similar objective under similar circumstances exercising reasonable business judgment. It is anticipated that the level of effort
may change over time, reflecting changes in the status of such Party and its circumstances, including, without limitation, the
market for the Products. “Commercially Reasonable” shall have the correlative meaning.

 

1.19.        “Company
Indemnified Parties” means Company, Company’s Affiliates, any of their successors or assigns, and any of their
respective then-current or then-former directors, officers, employees, contractors or agents.

 

1.20.        “Competitive
Entry” means an event in which prior to the Company receiving Regulatory Approval, another drug-device combination product
obtains regulatory clearance to begin marketing that [***], that could also be reasonably expected to compete favorably against
the Product in the Territory.

 

1.21.        “Components”
means, collectively, and without limitation, all container closure components (syringes, stoppers, etc.), raw materials, excipients,
device parts, and all Labels, necessary to Manufacture the Products in accordance with the NDAs, the Drug Master Files, and the
Specifications for the Products.

 

1.22.        “Confidential
Information” means all confidential, trade secret, proprietary or nonpublic information of a Party, including, without
limitation, all Know-How, scientific information, clinical data, efficacy and safety data, formulas, methods and processes, specifications,
pricing information (including discounts, rebates and other price adjustments), and other terms and conditions of sales, customer
information, business plans, and all other intellectual property, which is disclosed or made available to the other Party regardless
of whether such information is marked, identified as or otherwise acknowledged to be confidential at the time of disclosure to
the other Party.

 

1.23.        “Conforming”
or “Conform” means that the Product (a) conforms, in all respects, to the applicable Specifications, (b) was
Manufactured in accordance with cGMP and Applicable Law, and (c) is not adulterated or misbranded within the meaning of the Act
or within the meaning of any applicable state or municipal law in which the definitions of adulteration and misbranding are substantially
the same as those contained in the Act.

 

    	Page 3
	 

     

    

 

 

1.24.        “Control”
or “Controlled” means, with respect to any Know-How, materials, Patents or other intellectual property rights,
the legal authority or right (whether by ownership, license or otherwise but without taking into account any rights granted by
one Party to the other Party pursuant to this Agreement) of a Party to grant access, a license or a sublicense of or under such
Know-How, materials, Patents or other intellectual property rights to another Party, or to otherwise disclose proprietary or trade
secret information to such other Party, without breaching the terms of any agreement with a Third Party, or misappropriating the
proprietary or trade secret information of a Third Party.

 

1.25.        “Develop”
or “Development” means any activities related to the development of the Products, including but not limited
to, all formulation, process and method development, manufacturing, testing and release of all clinical/registration and scale-up,
Product validation, and packaging related to the Products for use in the Territory, on-going Product stability testing in accordance
with the Specifications and Applicable Laws, maintaining documentation of any stability testing conducted on the Products in accordance
with the Specifications and Applicable Laws, and any post-Launch stability testing.

 

1.26.        “Domain
Names” means any internet electronic addresses, uniform resource locators and alphanumeric designations associated therewith,
registered with or assigned by any domain name registrar, domain name registry or other domain name registration authority as part
of an electronic address on the internet, rights in social media accounts and social media pages, and all applications for any
of the foregoing.

 

1.27.        “Drug
Master File” or “DMF” means, with respect to the Product API, the drug master file or any supplement
thereto, filed by Company or its Affiliates or a Third Party with the FDA or other Regulatory Authority pursuant to the Act or
other Applicable Law.

 

1.28.        “Effective
Date” means the date this Agreement is signed by the last Party (as indicated by the date associated with such Party’s
signature on the signature page to this Agreement). Notwithstanding the foregoing, the effective date with respect to USWM’s
rights to the SYMJEPI product shall be the effective date of the termination of the Sandoz Commercial and Distribution Agreement
to which Company is a party.

 

1.29.        “Executive
Officer” means (a) the Chief Executive Officer of USWM or another officer of USWM designated by USWM, or an Affiliate
of USWM (the “USWM Executive Officer”), and (b) the President of Company or another officer of Company designated
by Company (the “Company Executive Officer”).

 

1.30.        “Force
Majeure Event” means an event impacting a Party due to causes beyond such Party’s reasonable control, including
without limitation, acts of God, pandemics or epidemics, national or regional emergency, any actions of governmental authorities
or agencies, government order or law, embargoes or blockades in effect on or after the Effective Date, war, hostilities between
nations (whether war is declared or not), terrorist threats or acts, civil commotions, riots or other civil unrest, national industry
strikes, lockouts, sabotage, labor stoppages or slowdowns or other industrial disturbances, shortage of adequate power or transportation
facilities, fire, floods and acts of nature such as typhoons, hurricanes, earthquakes, or tsunamis, or by any other event or circumstance
of like or different character to the foregoing beyond the reasonable control of such impacted Party.

 

    	Page 4
	 

     

    

 

 

1.31.        “FDA”
means the United States Food and Drug Administration, or any successor agency thereto.

 

1.32.        “GAAP”
means Generally Accepted Accounting Principles, as generally and consistently applied by USWM, and as may be updated or revised
from time to time by a decision of the Financial Accounting Standards Board or related accredited accounting entity.

 

1.33.        “Know-How”
means any information or material that is confidential and proprietary, including, without limitation, ideas, concepts, discoveries,
inventions, developments, improvements, know-how, trade secrets, designs, devices, equipment, process conditions, algorithms, notation
systems, works of authorship, computer programs, technologies, formulas, techniques, methods, procedures, assay systems, applications,
data, documentation, reports, chemical compounds, products and formulations, whether patentable or otherwise. Know-How shall also
include non-Confidential Information and material to the extent such information and material first lost its confidentiality by
virtue of its disclosure in an issued patent or published patent application, a filing with a Regulatory Authority or as part of
a legal proceeding.

 

1.34.        “Labels”
means any package, packaging material, labels, package inserts, instructions for use documents, patient prescribing information
and medication guides, as may be applicable, designed for use with the Products, pursuant to the terms of this Agreement, in accordance
with Applicable Laws, that is approved by the FDA.

 

1.35.        “Labeling”
means the act of preparing the Product with approved Labels (packaging in approved and serialized, as applicable, shipping containers,
boxes, cartons, applying approved prescribing inserts, etc.), pursuant to the terms of this Agreement, in accordance with Applicable
Laws.

 

1.36.        “Latent
Defect” means any adulteration, contamination of or other latent defect in any Product that is not readily detectible
upon visible inspection.

 

1.37.        “Launch”
means the first commercial sale of Product in the Territory by USWM or its Affiliates to a Third Party (including without limitation,
a wholesale, chain or retail pharmacy level) after receipt of the Launch Quantity. For purposes of this definition, “first
commercial sale” shall exclude sales for test marketing, clinical-trial purposes or compassionate use.

 

1.38.        “Launch
Quantity” means a mutually agreed quantity of Product Delivered by Company to USWM in advance of a Launch.

 

1.39.        “Liabilities”
or “Liability” means all losses, costs, damages, judgments, settlements, interest, fees or expenses including,
without limitation, all reasonable attorneys’ fees, experts’ or consultants’ fees, expenses and costs, related
to or arising from this Agreement or any of the Products developed, made, sold, marketed or otherwise distributed by the Parties.

 

    	Page 5
	 

     

    

 

 

1.40.        “Licensed
IP” means the Licensed Know-How and the Licensed Patents any intellectual property rights Controlled by Company or its
Affiliates that Company reasonably determines are necessary or useful for the Manufacture or Commercialization of the Products
in the Territory.

 

1.41.        “Licensed
Know-How” means Know-How Controlled by Company that is necessary or useful for the Manufacture and Commercialization
of the Products in the Territory.

 

1.42.        “Licensed
Patents” means any patents and patent applications Controlled by Company now or in the future that are necessary or useful
for Commercialization and Manufacture of the Products in the Territory. An initial list of Licensed Patents is set forth on Schedule
A. Schedule A will be updated by Company during the Term, as specified in Section 2.3.2 below.

 

1.43.        “Licensed
Trademarks” means the trademarks and Domain Names listed on Schedule A and any Domain Names Controlled by Company
during the Term related to such trademark.

 

1.44.        “Manufacture”
or “Manufacturing” means the commercial synthesis, manufacture, storage, handling, production, Processing, and
Labeling of the Products pursuant to this Agreement.

 

1.45.        “Manufacturing
Facility” means the manufacturing facilities of the Product Manufacturer, or such other facility under the control of
the respective Product Manufacturer that is approved by the FDA or other Regulatory Authority for manufacturing the Products.

 

1.46.        “Marketing
Year” means any calendar year during which the Products are Commercialized in the Territory. The first Marketing Year
for a Product shall be the calendar year in which its Launch occurs.

 

1.47.        “NDA”
means either new drug application 207534 (SYMJEPI) or 212854 (ZIMHI) filed by Company with the FDA, as may be amended or supplemented.

 

1.48.        “Net
Profit” means the amount (which shall not be less than zero dollars ($0.00)) calculated for a given Calendar Quarter
equal to Net Sales of the Products less the sum of (i) the Supply Price of Products sold by USWM in such Calendar Quarter, and
(ii) Additional Costs for the Products sold in such Calendar Quarter. Prior to [***]. Upon [***]. Notwithstanding the foregoing,
if and to the extent [***], then [***]. The costs of (i) and (ii) in this definition shall be calculated in accordance with GAAP,
to the extent applicable to such cost or calculation.

 

1.49.        “Net
Profit Share” means an amount equal to the percentage of Net Profits allocated to each Party as set forth on Schedule
B.

 

    	Page 6
	 

     

    

 

 

1.50.       “Net
Sales” means the net sales recorded by USWM or any of its Affiliates for sales of Product in the Territory to Third Parties
as determined in accordance with GAAP as consistently applied. The deductions booked on an accrual basis by USWM and its Affiliates
under GAAP to calculate the recorded net sales from gross sales consist of, without limitation, the following applied consistently:

 

		(i)	normal trade and cash discounts;

 

		(ii)	amounts repaid or credited by reasons of defects, rejections, recalls or returns, inclusive of
expiry and damage;

 

		(iii)	price protection and shelf stock adjustments, slotting fees and coupons;

 

		(iv)	rebates and chargebacks to customers and Third Parties (including, without limitation, group purchasing
organizations, Medicare, Medicaid, Managed Healthcare and similar types of rebates);

 

		(v)	any amounts recorded in gross revenue associated with goods provided to customers for free;

 

		(vi)	amounts provided or credited to customers through coupons and other discount programs;

 

		(vii)	delayed ship order credits, discounts or payments related to the impact of price increases between
purchase and shipping dates or retroactive price reductions;

 

		(viii)	fee for service payments to customers for any non-separable services (including compensation for
maintaining agreed inventory levels and providing information); and

 

		(ix)	other reductions or specifically identifiable amounts deducted for reasons similar to those listed
above in accordance with GAAP.

 

There shall be no double-counting in determining
the foregoing deductions. With respect to the calculation of Net Sales: (i) Net Sales only include the value charged or invoiced
on the first arm’s length sale to a Third Party and sales between or among USWM and its Affiliates shall be disregarded for
purposes of calculating Net Sales; and (ii) if a Product is delivered to the Third Party before being invoiced (or is not invoiced),
Net Sales will be calculated at the time all the revenue recognition criteria under GAAP are met. In the case of any sale or other
disposal for value, [***], of any Product, or part thereof, other than [***], Net Sales shall be calculated [***].

 

1.51.       “Person”
means any natural person, corporation, firm, business trust, joint venture, association, organization, company, partnership or
other business entity, or any government, or any agency or political subdivisions thereof.

 

1.52.       “Process”
or “Processing” means the compounding, filling, producing and/or packaging of the API and raw materials to produce
a Product in accordance with the applicable Specifications and the terms and conditions set forth in this Agreement.

 

1.53.       “Product”
or “Products” means the applicable definition set forth on Schedule D attached hereto.

 

    	Page 7
	 

     

    

 

 

1.54.       “Product
Liability Claim” means any product liability claims or action asserted or filed by a Third Party, seeking damages or
equitable relief of any kind, relating to personal injury, wrongful death, medical expenses, an alleged need for medical monitoring,
consumer fraud or other alleged economic losses, allegedly caused by the Products, and including claims by or on behalf of users
of the Products (including spouses, family members and personal representatives of such users) relating to the use, sale, distribution
or purchase of the Products sold by or on behalf of USWM in the Territory.

 

1.55.       “Product
Manufacturer” means the Third Party manufacturers of the Product set forth in Schedule G attached hereto, or as
otherwise agreed in writing by the Parties.

 

1.56.       “Profitability”
means the first Calendar Quarter in which a Net Profit is greater than zero (0).

 

1.57.       “Quality
Agreement” means the Quality Agreement that will govern the production of the Products and that will be executed by and
between USWM and Company in connection with this Agreement.

 

1.58.       “Regulatory
Approval” means the technical, medical and scientific licenses, registrations, authorizations and approvals required
for the manufacture, use, storage, import, transport, marketing, promotion, selling, and placing on the market of the Products
(including post-approval changes, pricing and Third Party reimbursement approvals, and Label approvals) by any Regulatory Authority
in the Territory. This includes any authorization necessary for the Manufacture, distribution, marketing, promotion, offer for
sale, use, import, export or sale of the Products as the context may require within the Territory.

 

1.59.       “Regulatory
Authority” means any applicable local, national or supranational government agency involved in assessing the Products
or granting approvals for the marketing and sale of the Products in the Territory.

 

1.60.       “Regulatory
Filing” means any filing made with a Regulatory Authority.

 

1.61.       “USWM
Indemnified Parties” means USWM, its Affiliates, any of their successors or assigns, and any of their respective then-current
or then-former directors, officers, employees, contractors, agents, successors or assigns.

 

1.62.       “Specifications”
means (i) with respect to the SYMJEPI 0.3mg Product, [***], and (ii) with respect to the SYMJEPI 0.15mg Product, [***]. In either
case of (i) or (ii) in this Section 1.62, “Specifications” shall also include the criteria set forth in the applicable
Regulatory Approval required for USWM’s acceptance of the respective Product from Company.

 

1.63.       “Supply
Price” means the amount Company shall invoice USWM as described in Schedule E attached hereto.

 

1.64.       “Territory”
means the fifty states of the United States of America, the District of Columbia, the Commonwealth of Puerto Rico, Guam, American
Samoa, the U.S. Virgin Islands and all territories and possessions of the United States of America, United States military bases
and any other territories the Parties mutually agree in writing to add to this Agreement, but excluding in all cases [***]. For
the avoidance of doubt, [***] does not include [***].

 

    	Page 8
	 

     

    

 

 

1.65.       “Third
Party” and the correlative term “Third Parties” means any Person or Persons other than a Party or any of
its Affiliates.

 

1.66.       Other
Defined Terms. Each of the following definitions is set forth in the Section of this Agreement indicated below:

 

	Definition	Section
	AAA	12.4
	Accelerated Net Profit Share Payments	6.2.3
	At Fault Recall	5.3.2
	Audited Party	6.5.2
	Auditing Party	6.5.2
	Branded Pharma Fee	6.3
	Commercial Efforts	Schedule F
	Commercial Plan	4.1
	Commercial Milestone Payments	Schedule C
	Commercialization Plan	4.1
	Company Elected Increase	4.2.4
	Delivery	3.6.1
	Dispute	12.3
	[***]	[***]
	Encumbrance	7.5.4
	Failure to Supply	11.2.2(a)
	Firm Commitment	3.2
	Firm Order	3.4
	Indemnitee	8.3
	Indemnitor	8.3
	Infringement Action	11.2.2(b)
	Initial Term 	11.1
	JPT	4.2.1
	Milestone Payments	6.1
	Near-Term Milestone Payments	6.1
	Net Profit Share Payments	6.2.2
	OPDP	4.5.2
	Order Confirmation	3.4
	Other Agreements	3.5.1
	Other Products	3.5.1
	Pharmacovigilance Agreement	5.4
	Product Changes	3.12.3
	Promotional Materials	4.5.1
	Purchase Order	3.3
	Quarterly Payment Date	6.2.2

 

    	Page 9
	 

     

    

 

 

	Definition	Section
	Quarterly Report	6.2.2
	Renewal Term	11.1
	Rolling Forecast	3.2
	Sales and Distribution Allocation	Schedule F
	Sales Taxes	6.4
	Sandoz	3.5.1
	Term	11.1
	USWM Legal Expenses	2.6.3

 

		2.	Exclusive distributorship; exclusivity.

 

2.1.         Appointment
of USWM as Exclusive Distributor in the Territory. Subject to the terms and conditions of this Agreement, (a) Company hereby
appoints USWM, and USWM hereby accepts, during the Term, to serve as the exclusive distributor (even as to Company) of the Products
in the Territory, and (b) Company grants to USWM the exclusive right (even as to Company) to market, sell, offer for sale, and
otherwise Commercialize the Products in the Territory under Company’s NDAs during the Term. Except as USWM may otherwise
agree in Other Agreements, USWM shall have the exclusive right to invoice and book all Product sales in the Territory during the
Term. Subject to the terms of this Agreement, USWM shall not have the right to grant any rights as subdistributor to any Third
Party except to the extent USWM’s agreements with specialty pharmacies, specialty distributors, group purchasing organizations,
wholesalers or similar entities that apply to Commercialization of the Products in the Territory contemplate such entities acting
as subdistributors.

 

2.2.         Supply
of Product for Distributorship. As provided in Section 3, Company shall supply (or have supplied) to USWM, and USWM shall purchase
from Company, its requirements of the Products for sale by USWM and its Affiliates in the Territory pursuant to Section 2.1.

 

2.3.         Licensed
IP.

 

2.3.1.       Subject
to the terms and conditions of this Agreement (including, without limitation, Section 12.9), Company hereby grants to USWM a fully
paid and exclusive (even as to Company), non-transferable and non-sublicenseable (except with the prior written consent of Company
to any such transfer or sublicense, such consent not to be unreasonably withheld, denied, conditioned, or delayed; provided however,
that such consent shall not be required to the extent the license is transferred or sublicensed to an Affiliate of USWM) license
under the Licensed IP for USWM to market, sell, offer for sale, and otherwise Commercialize the Products in the Territory under
this Agreement.

 

2.3.2.       Company
shall update the listing of Licensed Patents set forth in Schedule A on or before [***], so as to include information with
respect to [***]. If Company plans to [***], Company shall notify USWM in writing at least [***] in advance of [***]. Following
such notice, USWM will have the right, in its sole discretion, to [***]. Effective as of [***], such [***] shall [***].

 

    	Page 10
	 

     

    

 

 

2.4.         Licensed
Trademarks. Subject to the terms and conditions of this Agreement (including, without limitation, Section 12.9), Company hereby
grants to USWM a fully-paid, non-transferable and non-sublicenseable (except with the prior written consent of Company to any such
transfer or sublicense, such consent not to be unreasonably withheld, denied, conditioned, or delayed; provided however, that such
consent shall not be required to the extent the license is transferred or sublicensed to an Affiliate of USWM) license to use the
Licensed Trademarks only to market, sell, offer for sale and otherwise Commercialize the Products in the Territory under this Agreement,
which shall be exclusive (even as to Company). USWM and its Affiliates shall display the Licensed Trademarks on all Products and
on or in all packaging, promotion, and advertising materials to the extent practicable in a form and manner substantially in accordance
with the Trademark Usage Guidelines attached hereto in Schedule H and otherwise in compliance with all Applicable Laws.
At the reasonable request of Company from time to time, USWM will provide copies of packaging, Labels, advertising, promotional
and other material of USWM or its Affiliates referencing the Licensed Trademark to allow Company to confirm compliance with the
foregoing. In the event that Company has a reasonable objection, made in good faith, to the Licensed Trademark practices of USWM
or reasonably believes in good faith that USWM is not complying with the Schedule H guidelines, following an inspection
in accordance with the preceding sentence, as its sole remedy therefor, Company shall provide written notice to USWM of such objection
in reasonable detail to facilitate cure by USWM, and USWM shall use all Commercially Reasonable Efforts to cure and remedy the
objection. Approval of any particular practices, or use of any Licensed Trademark, once given by Company, shall continue in effect
with respect to such practices, or use, and any practices or use substantially consistent therewith, without need for further approval.

 

2.5.         Licensed
Trademark and Licensed Patent Filing, Prosecution, Maintenance and Costs.

 

2.5.1.      Company
shall be responsible for the preparation, registration, filing, prosecution and maintenance of the Licensed Trademarks, at its
sole cost and expense using reasonable care and skill and using counsel reasonably acceptable to USWM.

 

2.5.2.      Company
shall prepare, file and prosecute any and all patent applications and maintain any and all patents within the Licensed Patents.
Company shall pay for all prosecution, filing and maintenance fees and all other costs for prosecution, filing and maintenance
of any Licensed Patents associated with the Product in the Territory. Company shall use all reasonable care and skill and shall
use counsel reasonably acceptable to USWM in performing its obligations pursuant to this Section 2.5.2.

 

2.5.3.      In
performing its obligations under Sections 2.5.1 and 2.5.2, Company shall:

 

		a)	keep USWM reasonably informed of the filing and progress of all material aspects of the prosecution
of such trademark or patent application and the issuance of patents from any such patent application or the registration of any
such trademark;

 

    	Page 11
	 

     

    

 

 

		b)	provide USWM with a copy of such material patent application or trademark application, amendments
thereto, and other related correspondence to and from patent and trademark offices, and, to the extent reasonably practicable,
permit USWM an opportunity to offer its comments thereon before making a material submission to a patent and trademark office and
Company shall consider in good faith USWM’s comments;

 

		c)	consult with USWM concerning any decisions that could reasonably be expected to materially affect
the scope or enforcement of any issued claims or the potential abandonment of such patent application, patent, trademark application
or trademark; and

 

		d)	notify USWM in writing of any material changes in the scope or status of such patent, patent application,
trademark, or trademark application.

 

2.6.         Enforcement
of Licensed IP and Licensed Trademarks.

 

2.6.1.      If
either Party believes or becomes aware of (a) any suspected infringement of any Licensed IP or Licensed Trademark by a Third Party
in the Territory or (b) a Third Party allegation that any Licensed IP or Licensed Trademark is invalid or unenforceable, including
the receipt of a notice of certification filed pursuant to the Hatch-Waxman Act claiming that any of the Licensed IP is invalid,
unenforceable or that no infringement will arise from the manufacture, use or sale of the Product or a Competing Product by a Third
Party, or (c) Third Party allegation that the Product, or its use, development, manufacture, or sale infringes a Third Party’s
intellectual property rights in the Territory, such Party shall notify the other Party within [***] of forming such belief or awareness
and provide the other Party with all details of such infringement, claim, or notice, as applicable, that are known or possessed
by such Party.

 

2.6.2.      [***]
shall have the first right, but not the obligation, to bring an Infringement Action to enforce any Licensed IP or Licensed Trademark,
defend any declaratory judgment action concerning any Licensed IP or Licensed Trademark, and take any other lawful action reasonably
necessary to protect, enforce, or defend any Licensed IP or Licensed Trademark, and control the conduct thereof, and attempt to
resolve any claims relating to any Licensed IP or Licensed Trademark, including by (a) prosecuting or defending any inter partes
review, post-grant review, covered business method patent review, opposition, derivation, interference, declaratory judgment, federal
district court, state court, US Patent and Trademark Office, US International Trade Commission, or other proceeding of any kind,
and (b) taking any other lawful action that [***] believes is reasonably necessary to protect, enforce, or defend any Licensed
IP or Licensed Trademark. [***] has the right to prosecute or defend any such proceeding in [***] own name or, if required by applicable
law or otherwise necessary or desirable for such purposes, in the name of [***], and may join [***] as a party. [***] shall have
the right to control the conduct thereof and be represented by counsel of its own choice therein. Notwithstanding the foregoing,
if [***] does not bring an action with respect to any commercially significant Third Party infringement within [***] of [***] or
earlier notifies [***] in writing of [***], then [***] shall have the right, but not the obligation, to bring such an action and
to control the conduct thereof.

 

    	Page 12
	 

     

    

 

 

2.6.3.       Subject
to the subsequent sentence, in the event a Party undertakes the enforcement or defense of any Licensed IP or Licensed Trademark
in accordance with Section 2.6.2: (a) such Party will [***]; (b) the other Party shall provide all reasonable cooperation and assistance,
at the enforcing Party’s expense, including [***]; (c) in the event [***] undertakes the enforcement or defense, any recovery,
damages, or settlement derived from such suit, action, or other proceeding will be [***]; (d) in the event [***] undertakes the
enforcement or defense, any recovery, damages, or settlement derived from such suit, action, or other proceeding will be [***];
and (e) such Party may settle any such suit, action, or other proceeding, whether by consent order, settlement, or other voluntary
final disposition, without the prior written approval of the other Party, provided that [***] shall not settle any such suit, action,
or other proceeding in a manner that [***] without [***] prior written consent [***]. Notwithstanding the foregoing, in the event
(i) [***] undertakes the enforcement or defense of any Licensed IP or Licensed Trademark in accordance with Section 2.6.2, and
(ii) such enforcement or defense results in a final judgment or settlement [***] exceeds [***], then [***] shall be deducted from
[***].

 

2.6.4.       If
any suit, action, or other proceeding alleging invalidity or non-infringement of any Licensed IP or Licensed Trademark is brought
against [***] or any Affiliate, [***], at its option, will have the right, within [***] after commencement of such suit, action,
or other proceeding, to [***].

 

2.7.         License
of Third Parties’ Rights. In addition to the Company’s obligations pursuant to Section 8.1, in the event it is
necessary to obtain a license in the intellectual property rights of the Third Party in order for a Party to utilize any Licensed
IP or Licensed Trademarks to conduct activities for which it is responsible as contemplated by this Agreement, [***].

 

2.8.         Reserved
Rights. Company hereby expressly reserves all rights under the Licensed IP and Licensed Trademarks that are not expressly granted
to USWM under this Agreement, including, without limitation, rights under (a) the Licensed IP and Licensed Trademarks to research,
develop, make, have made, import, use, sell, offer for sale, distribute, promote, market, and otherwise Commercialize the Products
outside of the Territory, and (b) the Licensed IP to research, develop, make, have made, import, use, sell, offer for sale, distribute,
promote, market, and otherwise commercialize any and all products other than the Products (including any product other than the
Products that use any syringe to administer products) worldwide, provided, however, that the Company’s reservation of rights
in this Section 2.8(b) does not apply with respect to any products sold in the Territory containing epinephrine or naloxone (but
does apply to [***]), and (c) the Licensed IP and Licensed Trademarks to Manufacture, have Manufactured and supply the Products
for USWM and its Affiliates pursuant to this Agreement and to make, have made, package and have packaged the Products in the Territory
for Company and its Affiliates and licensees for use outside the Territory. If (i) the Company uses the Licensed IP to develop
and Commercialize, or permit the Licensed IP to be used to develop and Commercialize any products containing epinephrine or naloxone
in [***], or (ii) the Company or any of its Affiliates, directly or indirectly (e.g., by partnering with any Third Party), develops
or Commercializes any products containing epinephrine or naloxone in [***], then the Company agrees to [***]. Further, the Company
retains the right to reference and use, and grant to Company’s Affiliates and licensees (and their sublicensees) the right
to reference and use, all Regulatory Approvals for the Products in the Territory, including the NDA and the documentation comprising
the NDA, including all submissions, reports and correspondence relating to the NDA, and all data and information contained or referenced
therein (including all data and information from human factors, reliability and biocompatibility studies) as may be necessary or
useful (A) to perform Company’s obligations contemplated by this Agreement, and (B) in connection with any of the activities
described in Section 2.8(a), (b) and/or (c).

 

    	Page 13
	 

     

    

 

 

2.9.         No
Implied Licenses. Except as set forth in this Agreement, neither Party shall acquire any license or other intellectual property
interest, by implication or otherwise, under or to any patents, patent applications, Know-How or other intellectual property owned
or Controlled by the other Party.

 

2.10.       Mutual
Agreements.

 

2.10.1.       USWM
hereby covenants and agrees that during the Term it shall not (and cause its Affiliates not to), either itself or through a Third
Party, market, promote, sell or actively offer for sale the Products outside of the Territory. Without limiting the generality
of the foregoing, with respect to countries outside of the Territory, USWM shall not (i) engage in any advertising activities relating
to the Products directed primarily to customers located outside of the Territory (which excludes any participation in conferences,
congresses or scientific or medical meetings held throughout the world) or in the Territory for distribution outside the Territory,
or (ii) actively or intentionally solicit orders from any prospective purchaser of the Products for distribution outside of the
Territory. To the extent permitted by Applicable Law, if USWM receives any order from a prospective purchaser of the Products in
or for a country outside of the Territory, USWM shall immediately refer that order to Company and shall not accept any such order
or deliver or tender (or cause to be delivered or tendered) the Products under such order. If USWM is actually aware that a customer
or distributor has actively engaged itself or through a Third Party in the sale or distribution of the Products outside of the
Territory, then USWM shall, [***], unless otherwise agreed in writing by the Parties.

 

2.10.2.       Company
hereby covenants and agrees that during the Term it shall not (and shall cause its Affiliates, licensees and subcontractors not
to), either itself or through a Third Party, market, promote, sell or actively offer for sale the Products in the Territory. Without
limiting the generality of the foregoing, Company shall not (i) engage in any advertising activities relating to the Products directed
primarily to customers located in the Territory (which excludes any participation in conferences, congresses or scientific or medical
meetings held throughout the world) or outside of the Territory for distribution in the Territory, or (ii) actively or intentionally
solicit orders from any prospective purchaser of the Products for distribution in the Territory. To the extent permitted by Applicable
Law, if Company (or its Affiliates, licensees and subcontractors) receives any order from a prospective purchaser of the Products
in or for the Territory, Company shall immediately refer that order to USWM. If Company is actually aware that a customer or distributor
has actively engaged itself or through a Third Party in the sale or distribution of the Products in or for the Territory, then
Company shall [***].

 

    	Page 14
	 

     

    

 

 

3.            MANUFACTURING
AND supply services.

 

3.1.         Overview.

 

3.1.1.       Subject
to the terms and conditions of this Agreement, Company shall supply or have supplied to USWM, or its designee, the Products for
distribution and sale by USWM, or its Affiliates, in the Territory and Company shall not supply such Products to any Third Party
for sale in the Territory. USWM agrees that in no event shall USWM or its Affiliates Manufacture Product, have the Products Manufactured
by a Third Party, or purchase the Products from any party other than Company unless otherwise agreed in writing by the Parties.
Subject to the terms and conditions of this Agreement, Company shall be responsible for all costs related to Manufacturing and
supplying the Products to USWM.

 

3.1.2.       Except
as expressly provided in Sections 3.2, 3.3 and 3.5, USWM makes no guarantee or commitment, directly or indirectly, that USWM will
purchase any minimum quantity of the Products under this Agreement, and Company acknowledges that it will not conduct its business
in reliance on any such guarantee or commitment.

 

3.1.3.       The
Parties acknowledge and agree that Company will use the Product Manufacturers to Manufacture and supply (including making available
to USWM for shipping) the Products to USWM and its Affiliates under this Agreement. As of the Effective Date, the Third Parties
listed in Schedule G are the Product Manufacturers. If Company desires to delegate such Manufacturing and supply obligations
to a Product Manufacturer other than a Third Party that is listed in Schedule G [***] at any time during the Term, then
Company shall [***]. For purposes of clarity, except in the case of [***], it shall be deemed reasonable for [***], if such delegation
could [***]. Company shall be responsible for performance of Company’s obligations hereunder to the extent performed on Company’s
behalf by such subcontractor as if Company were itself performing such activities. The Parties acknowledge and agree that the terms
“Company shall” or “Company will” or the like, shall be deemed to be followed by the words “or the
Product Manufacturer, as a subcontractor of Company, will” or “or the Product Manufacturer, as a subcontractor of Company,
shall” or “Company shall require that the Product Manufacturer shall” or the like, with respect to Company’s
Manufacturing and supply obligations herein.

 

3.1.4.       Company
shall be responsible for all sourcing of all Components used in the Manufacture and Processing of the Products (including API,
excipients and primary packaging Components). The Company shall cause the Components to be manufactured under cGMP conditions,
as required by Applicable Law, and cause the Drug Master File to be maintained in good standing with the FDA during the Term.

 

3.2.         Rolling
Forecast. By the later to occur of (i) [***] after [***], or (ii) [***] prior to [***], USWM shall submit to Company a rolling
[***] forecast of Product that USWM intends to order from Company (the “Rolling Forecast”) for such period commencing
on the Launch. The first [***] of each Rolling Forecast shall be binding on the Parties (the “Firm Commitment”).
The remaining [***] of each Rolling Forecast shall be non-binding good faith estimates for planning purposes. On or about the [***],
USWM shall provide Company with an updated Rolling Forecast of both the revised Firm Commitment and the non-binding good faith
estimate.

 

    	Page 15
	 

     

    

 

 

3.3.         Purchase
Order. USWM shall provide purchase orders to Company concurrently with the submission of each Rolling Forecast which collectively
represent the quantity of the Products USWM would like Company to deliver to USWM during the Firm Commitment (“Purchase
Order”). Each Purchase Order shall specify: (a) USWM’s internal purchase order number, (b) the desired Batch quantity,
and (c) the desired date for Delivery.

 

3.4.         Firm
Order. Company shall supply to USWM those quantities of Products ordered by USWM pursuant to any accepted Firm Order within
the Firm Commitment. Company shall confirm to USWM each Purchase Order, including quantity, pricing and date for Delivery, in writing
(“Order Confirmation”) within [***] after receipt (or within [***] after receipt for a Purchase Order in excess
of the Firm Commitment). Each Order Confirmation shall either confirm the delivery date requested in the Purchase Order or provide
reasonable alternative date for Delivery. Company may reject any Purchase Order in excess of the Firm Commitment or otherwise not
given in accordance with this Agreement; provided, however, that Company shall [***] to supply USWM with quantities of the Products
which are in excess of the quantities specified in the Firm Commitment, subject to [***]. For clarity, Company will not be considered
in breach or default of this Agreement if it does not supply quantities of the Products which are in excess of [***]. USWM shall
have [***] following the receipt of an Order Confirmation, or such longer period as mutually agreed by the Parties, to cancel a
Purchase Order; thereafter the Purchase Order, under the terms of the Order Confirmation, shall constitute a binding contact (“Firm
Order”). Each Firm Order shall be considered a binding, non-cancellable commitment upon Company to produce and deliver
such quantities of the Products on the date for Delivery described there and upon USWM to purchase and pay for such Products; however,
the supply, purchase and sale of the Products shall be governed solely by this Agreement and any additional or contrary terms or
provisions contained in any Purchase Order, Order Confirmation, Firm Order or similar form or invoice or acknowledgment shall be
void and have no force or effect. Product shall be delivered to USWM no more than [***] from [***].

 

3.5.         Packaging;
NDC. Except (i) as may otherwise be agreed by the Parties in writing, and/or (ii) as set forth in Section 3.5.1, Company shall
supply USWM with the Products packaged in USWM’s trade dress under USWM’s NDC labeler code. Company shall cooperate
with USWM as required to support USWM obtaining its own NDC labeler codes for the Products. USWM shall supply to Company information
and materials regarding USWM’s trade dress and NDC labeler codes and any standards and instructions for Product packaging
that USWM requests in sufficient time to permit Manufacturing and supply of the Products in accordance with this Agreement. USWM
acknowledges that a failure by USWM to provide the requirements for Labels including, but not limited to, USWM trademarks, trade
names, packaging graphics, serialization codes and NDC numbers, within the timeframe specified by Company could delay the Delivery
of the Launch Quantity. USWM shall be responsible at its sole cost for ensuring that all such information, materials, standards
and instructions comply with Applicable Laws. Company shall provide USWM with all documentation regarding the Products reasonably
requested by USWM to allow USWM to complete a country of origin evaluation pursuant to Applicable Laws.

 

3.5.1.       Other
Agreements. To the extent that the Parties enter in one or more agreements (“Other Agreements”) with Sandoz
Inc. (“Sandoz”) concerning activities relating to the past, present or future commercialization, distribution,
marketing or sale of [***] (“Other Products”), as between USWM and Company, (i) [***], and (ii) [***].

 

    	Page 16
	 

     

    

 

 

3.6.         Delivery
Terms.

 

3.6.1.       Company
or the Product Manufacturer shall deliver the Product ExWorks (Incoterms2010) in accordance with the delivery date determined according
to Section 3.4 (“Delivery”). For the avoidance of doubt, Company shall not be responsible for the Products in
transit, including any cost of insurance or other transport fees for the Products, or any risks associated with transit, storage
and handling. Company shall provide delivery information [***]; however, USWM shall be [***], in accordance with the terms of the
Quality Agreement.

 

3.6.2.       If
the requested quantity of the Products cannot be delivered on the delivery date determined according to Section 3.4, Company shall
notify USWM within [***] of becoming aware of such delivery issue.

 

3.7.         Documentation.
With each shipment of the Products, Company shall, or shall cause its Product Manufacturer to, provide all documentation in the
possession or control of Company or the Product Manufacturer as is reasonably required by any Regulatory Authority from time to
time in connection with the Manufacture of the Products.

 

3.8.         Storage.
Company shall maintain and store all Product in accordance with the Specifications and Good Manufacturing Practices at all times,
pending Delivery to USWM. Company’s actual out of pocket costs incurred to comply with this Section 3.8 shall be [***].

 

3.9.         Serialization
and Coding. Company shall implement Product serialization and coding in accordance with Applicable Laws. USWM and Company will
work together to align on implementation. USWM acknowledges that a failure by USWM to provide the requirements for serialization
including, but not limited to, GTIN, bar codes, bulk serialization numbers and links between Product Manufacturer and USWM’s
third-party logistics (3PL) provider, within the timeframe specified by Company could delay the Delivery of the Products. The cost
of setting up the relevant equipment and the capability for online coding, creating unique serial numbers and its aggregations
including necessary IT systems required for data storage and data exchange in order to pack the Products to meet the regulations
in the Territory shall be borne by Company or its Product Manufacturer.

 

3.10.       Inspection
and Acceptance.

 

3.10.1.       Company
shall test and inspect each Batch of Product for compliance with the Specifications prior to the release and shipment thereof to
USWM. Company shall provide a Certificate of Analysis, Certificate of Conformance, Certificate of Release or other Certificate
with each shipment of each Batch of Product. The Certificate(s) must evidence that the Product conforms to [***].

 

3.10.2.       USWM,
or a qualified Third Party designated by USWM, may, but is not obligated to, test and inspect the Products after receipt of each
Batch of Product. USWM may reject any shipment (or portion thereof) of Product if it does not Conform based on such inspection
by written notification to Company within [***] of [***]. USWM shall be deemed to have accepted the Product if USWM fails to give
written notice of rejection within [***] of [***], except in the case of [***] in which case such written notice of rejection must
be provided within [***]. The written notice of rejection shall be given to Company and shall include identification of the lot
number and description of the basis for rejection.

 

    	Page 17
	 

     

    

 

 

3.10.3.       Following
receipt of written notice of rejection of a particular Batch of Product, Company shall notify USWM in writing within [***] of receipt
of such notice from USWM whether Company disagrees with the rejection and, if Company does not provide such written notice within
such [***] period, Company will be deemed to agree with such rejection. If Company provides written notice of disagreement with
the rejection in accordance with the preceding sentence, the following procedures shall apply: the Parties shall review the test
results and attempt to reach agreement as to whether or not the Product fails to Conform and if they fail to reach agreement within
[***] after delivery of the written notice of disagreement provided by Company to USWM, the Parties shall designate a mutually
acceptable Third Party laboratory to make a determination on such matter from a sample obtained from the rejected Batch of Product.
The decision of the Third Party laboratory shall be binding on all Parties hereto and all expenses related to such Third Party
investigation shall be borne by the Party found to have been mistaken. Should such Third Party laboratory confirm USWM’s
claim, Company shall, at USWM’s request, promptly provide USWM with [***].

 

3.10.4.       If
the Parties agree to the rejection of any Batch (or portion thereof) of Product or the Third Party laboratory confirms rejection
of any Batch (or portion thereof) of Product, USWM shall return, destroy, or cause to be destroyed any rejected Product to Company
at Company’s expense to an address that Company shall designate within [***] of the agreement or Third Party laboratory determination
regarding rejection, as applicable, and Company, at USWM’s request, will promptly provide USWM with a credit or refund of
the Supply Price for the rejected Product if USWM has already paid Company for such rejected Product or will promptly provide replacement
Product to USWM subject to USWM’s payment of the Supply Price for replacement Product unless USWM has already paid Company
for such rejected Product, together with [***]. If Company, however, does not agree with USWM’s claim of non-compliance with
the Specifications or other defect, USWM shall not be obligated to return the rejected Product to Company until after a final determination
is made by a Third Party laboratory that such Product does not comply with the applicable Specifications or is otherwise defective.
Absent such designation of address, USWM shall ship rejected Product to the location of the Manufacturing Facility. If the Third
Party laboratory determines that the Batch was not correctly rejected, then USWM shall pay Company the Supply Price for such Batch
and for any replacement Product (for purposes of clarity, USWM’s payment of the Supply Price for such Batch shall not be
a duplicative payment).

 

3.11.       Supply
Price and Payment.

 

3.11.1.       Solely
to the extent otherwise included in the Supply Price (as the term is defined in Section 1.63 hereto), Company shall send an invoice
to USWM covering such Firm Order. The Supply Price shall be invoiced in U.S. dollars.

 

3.11.2.       USWM
shall pay each undisputed invoice no later than [***] after receipt of such invoice by USWM. Payments by USWM to Company, including,
but not limited to, any final payment by USWM to Company, shall not be deemed as an acknowledgement by USWM that Company has performed
properly or that Company has fulfilled its contractual obligations, regardless of whether the respective payments were made with
any reservation.

 

    	Page 18
	 

     

    

 

 

3.11.3.       The
Supply Price may be adjusted based on (i) [***], (ii) [***], and (iii) [***] upon [***] prior written notice to USWM; provided,
however, that Company shall provide USWM reasonable documentation [***], and USWM may audit such [***] pursuant to Section 3.13.

 

3.11.4.       During
the Term, Company shall [***] to [***].

 

3.12.       Specifications
& Quality.

 

3.12.1.       Company
shall cause the Product Manufacturer to Manufacture the Products in strict conformity with the Specifications. Further, Company
represents that, as of the Effective Date and during the Term, the Product Manufacturer holds the required manufacturing authorization
pursuant to Applicable Laws for the Manufacture of the Products.

 

3.12.2.       Within
[***], USWM and Company (and/or the Product Manufacturer, as applicable) shall enter into a mutually agreeable Quality Agreement
relating to the Products. Company shall maintain a current Quality Agreement and quality control system compliant with the Regulatory
Authority for the Products to be delivered hereunder. Such a system shall include [***]. Each Batch of Product to be supplied to
USWM hereunder shall be subject to a quality control inspection by Company in accordance with Company’s then current quality
assurance standards and the approved Regulatory Filings. In the event a conflict arises between the Quality Agreement and this
Agreement, the term contained in the Quality Agreement shall control with respect to quality-related matters relating to the Products.

 

3.12.3.       [***]
modifications, changes, additions or deletions to the (1) [***]; (2) [***]; (3) [***]; (4) [***]; (5) [***]; (6) [***]; (7) [***];
or (8) [***], which Company intends to carry out (hereinafter, “Product Changes”), must be evaluated and documented
by [***]. Prior to implementation of any material Product Change, and in any event, within [***] from [***], Company agrees to
provide reasonable notice to USWM in writing of such change and Company shall consider in good faith any input timely provided
by USWM regarding any Product Changes. Reasonable notice applies in (1) circumstances in which [***], and (2) circumstances where
[***]. In such circumstances, following reasonable notice, USWM shall be informed of [***]. If appropriate and upon considering
in good faith timely input provided by USWM, Company shall [***].

 

3.12.4.       Company
is responsible for storing and maintaining retention samples of each Batch of Product produced for USWM for [***] in accordance
with Good Manufacturing Practices and the terms of the Quality Agreement. Company will take measures to ensure that the quantity
of retention samples shall be of sufficient quantity [***].

 

3.12.5.       Company
shall be responsible for the testing and generation of stability data for the Products in accordance with the cGMP and ICH guidelines.

 

    	Page 19
	 

     

    

 

 

3.12.6.       Company
shall be responsible for confirming that all facilities (including the Manufacturing Facility), utilities, equipment and the processes
utilized to Manufacture the Products are satisfactorily validated according to the guidelines of all applicable Regulatory Authorities,
Applicable Laws, and cGMP.

 

3.12.7.       Records
which include the information relating to the Manufacturing, packaging and quality operations for each Batch of Product shall be
prepared by Company for each lot at the time such operations occur. Such records shall be prepared in accordance with Applicable
Laws and Company’s standard operating procedures. Company shall keep Batch Records, and all associated batch documentation
(i.e., deviations, testing data, testing results, Batch release documentation, etc.), for each Batch of Product until the later
of (i) the period of time required by Applicable Law, or (ii) [***].

 

3.13.       Manufacture
and Supply Records; Audit Rights.

 

3.13.1.       Company
shall maintain (a) complete, accurate and systematic written records of the Manufacture and supply of the Products in the Territory
to USWM, and (b) records relating to quality and Manufacturing processes and control steps. Such records shall be maintained for
a period of at least [***] or longer if required under Applicable Laws or the Quality Agreement.

 

3.13.2.       On
reasonable prior notice, Company shall allow employees or authorized representatives of USWM and/or its Affiliates to perform an
audit of any documents, records or any facility, including the Manufacturing Facility, involved in the Processing or Manufacturing
of the Products, including, but not limited to, any such documents and records and facility related to the API and Product intermediates,
subject to the following sentence with respect to subcontractors. In case that any subcontractor is involved (including, without
limitation, any Product Manufacturer), Company shall (i) upon request, provide USWM and/or its Affiliates with the report of the
audits carried out by or on behalf of Company of any such subcontractor or any other documents and information necessary for USWM
to verify compliance of such subcontractors with Applicable Laws and this Agreement; and (ii) use [***] to cause [***].

 

3.13.3.       USWM
shall also have the right to conduct “for-cause” audits to address significant Product or safety concerns as discovered
through Product failures related to the Manufacture of the Products. Product failures shall include [***]. USWM shall notify Company
in writing in advance of the audit and thereafter, with Company’s reasonable assistance, the Product Manufacturer and USWM
shall mutually determine the timing of the audit.

 

3.13.4.       In
the event Company’s (or its Product Manufacturer’s) Manufacturing, packaging, testing or storage facility(ies), including
the Manufacturing Facility, producing the Products is/are inspected by representatives of any Regulatory Authority in connection
with Company’s (or its Third Party contractor’s) Manufacture of the Products, Company will notify USWM promptly upon
learning of such inspection, and will, to the extent permitted by Applicable Laws and Company’s agreements with its Third
Party contractors, supply USWM with copies of any correspondence or communications or portions thereof which relate to the Products.

 

    	Page 20
	 

     

    

 

 

3.14.       Manufacturing
Facility. As of the Effective Date, the Manufacturing Facility is deemed to be Catalent [***]. As of the Effective Date, the
Manufacturing Facility has any and all Regulatory Approvals required for the Manufacture, Labeling, packaging, and exportation
of the Products in accordance with the Specifications, cGMP and Applicable Laws, and thereafter Company will use [***] to ensure
that the Manufacturing Facility shall maintains any and all such Regulatory Approvals.

 

4.            COMMERCIALIZATION.

 

4.1.         Commercialization.
USWM shall Commercialize the Products in the Territory in accordance with Applicable Law and shall use [***], including [***],
to Commercialize the Products in the Territory in accordance with [***].

 

4.2.         Joint
Project Team.

 

4.2.1.       Formation.
Promptly after the Effective Date, the Parties will form a Joint Project Team (“JPT”) comprised of [***] representatives
from Company and [***] representatives from USWM. [***].

 

4.2.2.       Purposes.
The purpose of JPT meetings will be to discuss the Launch and Commercialization of the Products according to the applicable provisions
of this Agreement, including planned Commercial Efforts, improvements to [***], as well as [***]. Additionally, the JPT shall discuss
and approve the Sales and Distribution Allocation for the future Marketing Year.

 

4.2.3.       Disputes.
The JPT will operate [***]. The decisions made and the actions taken by the JPT will be made with the interests of both Parties
duly considered in good faith. Subject to the terms of this Agreement and Applicable Law, the decisions of the JPT will be made
in accordance with the discretion and business judgement of the members thereof. [***].

 

4.2.4.       Limited
Authority. For purposes of clarity, the failure of the JPT in [***] will not be deemed to constitute a breach of this Agreement
by either Party. In no case shall the JPT have any authority to (i) [***], (ii) [***], (iii) [***], and/or (iv) [***].

 

4.2.5.       Company
Elected Increase. If the JPT is unable to [***], the Company may elect, at its sole discretion, to [***].

 

4.2.6.       Meetings.
The JPT will meet in person or by teleconference on a quarterly basis, or at such other frequency as the JPT agrees. The Parties
will agree upon the time and place of such meetings. Within [***] days after each meeting, [***].

 

4.3.         Sales
and Distribution; Returns. USWM shall be responsible for handling all returns, recalls, order processing, invoicing and collection,
distribution, and/or receivables for the Products Commercialized by USWM in the Territory pursuant to this Agreement. The cost
of any recall shall be allocated pursuant to Section 5.3. USWM shall book all sales of the Products in the Territory.

 

    	Page 21
	 

     

    

 

 

4.4.         Pricing.
The JPT will discuss pricing strategy in general, however, USWM will have final discretion in determining the pricing, terms
of sale, marketing, and selling decisions for the Products in the Territory.

 

4.5.         Advertising
and Promotional Materials.

 

4.5.1.       Excepting
for such advertising and Promotional Materials, if any, which are provided to USWM by the Company, USWM shall prepare and produce
all Promotional Materials for Commercialization of the Products in the Territory. In relation to the Products, USWM shall determine
the manner in which information will be presented and described to the medical community in any Promotional Materials or other
materials related to the Products for sale in the Territory. USWM shall own all right, title and interest in and to any and all
such Promotional Materials it develops, including all applicable copyrights, trademarks (other than the Licensed Trademarks, which
are licensed to USWM under Section 2.4), program names and domain names for Products to be sold by USWM in the Territory. For purposes
of this Agreement, “Promotional Materials” means all sales, marketing, and advertising materials as defined
in the Act for the Products to be sold by USWM in the Territory.

 

4.5.2.       USWM
shall be solely responsible for developing, filing and making decisions with respect to all Promotional Materials and associated
regulatory materials, including all filings and interactions with the FDA’s Office of Prescription Drug Promotion (“OPDP”).
The Parties shall jointly notify the FDA of Company’s delegation of such responsibility for the Products to be sold by USWM
in the Territory to USWM. USWM shall provide Company with a copy of each such filing promptly after submission thereof. For the
avoidance of doubt, USWM will retain exclusive authority and responsibility for the filing of Promotional Materials with the FDA
on Form 2253 (or such other form as required by the FDA) or as otherwise required by, or permitted under, Applicable Laws. USWM
shall promptly, but in any case, within three (3) Business Days of receipt, provide Company with complete copies of all material
correspondence relating to Promotional Materials for the Products with Regulatory Authorities, including OPDP.

 

4.5.3.       USWM
Trademarks. All trademarks, trade names and packaging graphics owned or licensed by USWM and intended to be used in connection
with the Products will be chosen by USWM in its sole discretion. Additionally, in the event the Licensed Trademark(s) cannot be
used in connection with the Commercialization of the Products in the Territory because of legal, safety and/or regulatory reasons,
USWM shall select and work with Company to obtain regulatory acceptance for an alternative trademark or trade name for such use
and shall file and register appropriate registrations for such trademark with the USPTO. USWM shall own such alternative trademark
and all goodwill associated therewith.

 

4.6.         Medical
Information. USWM shall determine procedures for responding in a consistent manner to medical information requests on the Products
in the Territory. USWM shall be solely responsible for responding to all medical information requests and for providing support
and responding to product and medical complaints relating to the Products in the Territory; provided, that, Company shall cooperate
with and assist USWM upon USWM’s reasonable request with regards to such activities.

 

    	Page 22
	 

     

    

 

 

5.            regulatory
matters.

 

5.1.         Regulatory
Approval; Regulatory Authority Communications.

 

5.1.1.       Except
as otherwise mutually agreed by the Parties, Company will be responsible for all regulatory and registration activities for the
Products in the Territory at Company’s sole cost and expense (except as set forth in Section 4.5.2), including, but not limited
to, being solely responsible for interacting with FDA for the purpose of obtaining and maintaining the Regulatory Approval for
the Products. Except as otherwise mutually agreed by the Parties, Company shall be responsible for conducting all nonclinical and
clinical studies; device design and testing; chemistry, manufacturing and controls related activities, and manufacturing process
validations necessary for Regulatory Approval or required by a Regulatory Authority as a condition to, or in connection with the
grant or maintenance of a Regulatory Approval, encompassing both registration and post-marketing commitment/ requirement activities.
At each meeting of the JPT, Company will present and discuss the status of all of the registration and/or post-marketing commitment/requirement
activities that Company has performed or caused to be performed pursuant to this Section 5.1.1 since the last meeting of the JPT.
Company shall perform any work necessary in response to FDA deficiencies connected with initial registration, application supplement,
or post-marketing commitment/requirement and Company shall keep USWM informed of the status of all such activities on a regular
basis.

 

5.1.2.       In
addition to the requirements set forth in 5.1.1, Company shall provide USWM with written notice of meetings with the FDA regarding
the Products. Company shall consider in good faith any input timely provided by USWM regarding regulatory activities relating to
the Products in the Territory and will promptly update USWM on the results of such regulatory activities. Upon request, Company
shall promptly provide to USWM complete copies of all material correspondence with Regulatory Authorities regarding the Products.

 

5.1.3.       Company
acknowledges that it is not authorized to and agrees that it shall not interact directly with government agencies, entities or
authorities on behalf of USWM without the prior written authorization of USWM. In the event that such interaction with government
agencies, entities or authorities is authorized in writing, it is agreed that certain due diligence, additional inquiries, and
potentially other agreed upon measures will be required prior to or coincident with such authorization being granted and that this
Agreement may also need to be amended to include certain standard provisions including regular satisfactory reviews and updated
due diligence by USWM and its agents relating to Company.

 

5.2.         Regulatory
Costs. Company shall be responsible for paying all regulatory fees that are payable to a Regulatory Authority relating to the
Products, including, without limitation, the PDUFA program user fee for the Products (and any other similar or related fees required
by similar laws, rules or regulations, including any annual fees owed to any Regulatory Authority with respect to the Products).

 

5.3.         Product
Withdrawals and Recalls.

 

5.3.1.       The
Parties agree that each Party shall consult with the other Party and the Parties shall jointly cooperate in all recalls, but that
Company shall be responsible for providing proper notification of a Product recall or Product withdrawal to the applicable Regulatory
Authority(ies). With respect to the Products Commercialized by USWM in the Territory, in the event that: (a) any Regulatory Authority
in the Territory issues a request, directive or order that Product be recalled or retrieved; (b) a court of competent jurisdiction
orders that Product be recalled or retrieved; or (c) USWM reasonably determines, after reasonable, good faith discussion with Company,
that Product should be recalled or retrieved, USWM shall promptly notify Company of such event and both Parties shall cooperate
in relation to the recall. USWM shall be responsible for the final recall decision, communication to the public, and the logistic
process regarding returned goods.

 

    	Page 23
	 

     

    

 

 

5.3.2.       [***]
shall be responsible for administering any recall and [***] shall bear the cost of a recall and shall reimburse [***] for [***],
in each case including [***], unless the recall is determined to be caused by [***], in which event [***] shall bear the cost of
that recall and shall reimburse [***] for [***].

 

5.4.         Safety
Reporting. Within [***], the Parties shall enter into a mutually agreeable, commercially reasonable pharmacovigilance agreement
for the purpose of providing detailed procedures regarding the exchange of safety data and information regarding the Products and
for ensuring compliance with reporting requirements of Regulatory Authorities (the “Pharmacovigilance Agreement”).
The Pharmacovigilance Agreement shall provide, among other things, that Company shall (at its sole cost) be, or shall cause a Third
Party to be, responsible for maintaining the safety database for the Products and reporting safety-related information to the FDA;
provided, that, Company shall be responsible for performance of Company’s obligations under the Pharmacovigilance Agreement
to the extent performed on Company’s behalf by such Third Party as if Company were itself performing such activities. [***]
will be [***] responsible for [***] incurred by [***] related to [***]. In the event a conflict arises between any pharmacovigilance
term in this Agreement and a term in the Pharmacovigilance Agreement, the term contained in the Pharmacovigilance Agreement shall
prevail.

 

5.5.         Compliance
with Government Pricing, Government Programs and State/Federal Pricing Transparency Regulations. USWM shall be solely responsible
for all federal, state and local government purchasing, pricing or reimbursement programs and private purchasing, pricing or reimbursement
programs with respect to the Products sold by USWM pursuant to this Agreement, including taking all necessary and proper steps
to execute agreements and file other appropriate reports and other documents with Regulatory Authorities and private entities necessary
for coverage of the Products under state, federal or other health care programs and to list the Products under such agreements
as appropriate. USWM shall be responsible for categorizing the Products under federal, state and local government pricing or reimbursement
programs in the Territory. USWM shall respond to all state and federal regulations on pricing transparency. In connection with
the foregoing, Company will promptly provide USWM with any information and supporting documentation with respect to the Products,
which is within Company’s possession or control, that is required to support all government pricing calculations including
product classifications, baseline AMP value and period or state/federal regulations/legislation related to government pricing,
Medicaid liabilities or pricing transparency regulations (current and future).

 

    	Page 24
	 

     

    

 

 

6.            FINANCIALS.

 

6.1.         Milestone
Payments. During the Term, USWM will make: (a) the one-time, non-refundable, non-creditable Near-Term Milestone Payments, and
(b) the one-time, non-refundable, non-creditable Commercial Milestone Payments, both set forth on Schedule B and Schedule
C, respectively (collectively the “Milestone Payments”) to the Company upon successful completion of the
corresponding milestone events. Each Party shall promptly notify the other Party upon the occurrence of a milestone (as applicable)
which may occur prior to the completion of a Quarterly Report referenced in Section 6.2.2 below, and the Company shall thereafter
issue an invoice to USWM for the applicable Milestone Payment. Milestone Payments shall be due as described in Schedule B
and Schedule C.

 

6.2.         Net
Profit Sharing.

 

6.2.1.       Net
Profit Allocation Percentages. Except as otherwise provided herein, during the Term of this Agreement, Company will be entitled
to a payment from USWM equal to its allocated percentage of Net Profit Share, as more fully set forth on Schedule B attached
hereto. USWM shall retain the remaining percentage of Net Profit Share.

 

6.2.2.       Net
Profit Share Payments. All Net Profit Share allocation payments made by USWM to Company will be made on a quarterly basis.
Within [***] after the end of an applicable Calendar Quarter, USWM shall provide Company with a report showing units sold, Net
Sales, deductions from Net Sales, the Net Profit Share allocations and [***] (“Quarterly Report”). Within [***]
after the end of the applicable Calendar Quarter (such date, the “Quarterly Payment Date”), USWM shall provide
Company with a cash payment equal to the Net Profit Share stated in the latest Quarterly Report.

 

6.2.3.       Accelerated
Net Profit Share Payments. In the absence of [***], beginning with [***], USWM shall pay [***] to the Company as defined in
Schedule B until [***]. After such [***], the [***] will revert to [***]. If [***] precedes [***], then no Accelerated Net
Profit Share Payments shall be due, however, [***].

 

6.2.4.       [***]
Reports. In addition to the quarterly reports described in Section 6.2.2, within [***] after [***], USWM shall provide Company
with a report (in Microsoft excel format or any other format reasonably agreed to by the Parties) that includes (i) [***], and
(ii) [***].

 

6.3.         Branded
Prescription Drug Fees. By means of [***], the Parties shall [***] any applicable Annual Branded Prescription Drug Fees owed
with regard to the Products, including under Section 9008 of the Patient Protection and Affordable Care Act (ACA), Public Law 111-148
(124 Stat. 119 (2010)), as amended by section 1404 of the Health Care and Education Reconciliation Act of 2010 (HCERA), Public
Law 111-152 (124 Stat. 1029 (2010)), or any successor laws (the “Branded Pharma Fee”). Each [***], USWM shall
[***]. Such amount is subjected to [***].

 

    	Page 25
	 

     

    

 

 

6.4.         Taxes.
All amounts payable by USWM to Company under this Agreement are exclusive of any tax, levy or similar governmental charge that
may be assessed by any jurisdiction, whether based on gross revenue, the Manufacturing, sale, storage, Delivery, possession or
use of the Products, the execution or performance of this Agreement or otherwise. If any payment under this Agreement by USWM to
Company is subject to withholding tax under Applicable Law, USWM shall have the right to withhold any and all such taxes, which
shall be paid to the appropriate taxing authority for the account of Company and such payments to Company shall be net of the applicable
withholding taxes. USWM shall provide to Company appropriate proof of payment of any and all taxes so withheld. The Parties agree
to cooperate to minimize any withholding taxes (including providing each other with any exemption certificates or other documentation
establishing that no taxes are due, or such taxes are due at a reduced rate). Additionally, all charges made by Company to USWM
hereunder for the supply of the Products is exclusive of any sales, use, value added, or similar tax customarily borne by a purchaser
(“Sales Taxes”). If Company has a legal obligation to collect or charge Sales Taxes, [***] and [***]. Other
than as provided in this Section 6.4, each Party shall be responsible for its own taxes, including but not limited to any tax,
fee, assessment or other charge based on or measured by the capital or net income, or any other tax imposed by any jurisdiction.

 

6.5.         Financial
Records; Audits.

 

6.5.1.       During
the Term, the Parties shall maintain complete and accurate Books and Records for the purpose of determining the amounts paid or
payable pursuant to this Agreement. Such Books and Records shall be kept for such period of time required by Applicable Laws, but
no less than at least [***]. Such records shall be subject to inspection in accordance with Section 6.5.2.

 

6.5.2.       Upon
[***] prior written notice and no more than [***] for each category of costs or revenues, a Party (“Audited Party”)
will permit its Books and Records for the prior calendar year to be examined for any cost, expense, Supply Price, Net Sales or
Net Profit for which it may owe a payment to the other Party [***], during normal business hours, by an independent auditor appointed
by the other Party (“Auditing Party”) and reasonably acceptable to the Audited Party, and at the Auditing Party’s
expense (and the Auditing Party shall not compensate such auditor on a contingent fee basis), to the extent necessary to verify
the accuracy of the amounts paid by the Audited Party to the Auditing Party pursuant to this Agreement. Any information received
as a result of such inspection will be maintained as the Audited Party’s Confidential Information. In the event that an examining
auditor concludes any underpayment or overcharging by any Party, the auditor will specify such underpayment or overcharging in
a written report, along with the information on which such conclusion is based. This report will be shared promptly with the Audited
Party. The underpaying or overcharging Party shall remit such underpayment or reimburse such overpayment to the underpaid or overcharged
Party within [***] of the date of such report, provided, that if a Party disputes the conclusion of the auditor, the Parties will
attempt to resolve the dispute according to Section 12.3. Further, if the audit for an audited period shows an underpayment or
an overcharge by any Party for that period in excess of [***] of the amounts properly determined, the underpaying or overcharging
Party, as the case may be, shall reimburse the applicable underpaid or overcharged Party conducting the audit, for its respective
audit fees and reasonable out-of-pocket costs in connection with such audit, which reimbursement shall be made within [***] after
receiving appropriate invoices and other support for such audit-related costs.

 

    	Page 26
	 

     

    

 

 

6.6.         Disclaimer.
Notwithstanding USWM’s obligations to meet the Commercial Efforts set by the JPT, Company acknowledges that USWM makes no
further representation, warranty or covenant, either express or implied, that (a) USWM will succeed in Commercializing the Products
in the Territory, (b) the Products will achieve any particular sales level, or (c) achievement of any Commercialization Plan guarantees
the achievement of any particular future sales level within any given period of time, if at all.

 

7.            REPRESENTATIONS
AND WARRANTIES.

 

7.1.         Corporate
Power. Each Party hereby represents and warrants that such Party is duly organized, validly existing, and in good standing
under the laws of its jurisdiction of formation and organization and has full corporate power and authority to enter into this
Agreement and to carry out the provisions hereof.

 

7.2.         Due
Authorization. Each Party hereby represents and warrants that such Party is duly authorized to execute and deliver this Agreement
and to perform its obligations hereunder throughout the term of this Agreement. Each Party hereby represents and warrants that
the execution of this Agreement by its representative whose signature is set forth at the end hereof has been duly authorized by
all necessary organizational action of the Party.

 

7.3.         Binding
Obligation. Each Party hereby represents and warrants that this Agreement, when executed, is a legal and valid obligation binding
upon it and is enforceable against that Party in accordance with its terms. The execution, delivery and performance of this Agreement
by such Party does not conflict with any agreement, instrument or understanding, oral or written, to which it is a party or by
which it may be bound, nor violate any law or regulation of any court, governmental body or administrative or other agency having
authority over it.

 

7.4.         Compliance
with Applicable Laws. Company represents, warrants and covenants to USWM that (i) it has complied, and is now complying, with
all Applicable Laws applicable to the conduct of the Business as currently conducted or the ownership and use of the Products,
and (ii) it shall, at all times, comply with all Applicable Laws in its performance of its obligations pursuant to this Agreement.
USWM represents, warrants and covenants to Company that it shall, at all times during the term of this Agreement, comply with all
Applicable Laws in its performance of its obligations pursuant to this Agreement.

 

7.5.         Additional
Company Representations and Warranties. Company hereby represents and warrants that:

 

7.5.1.       The
Licensed Patents listed on Schedule A represent all Patents that Company or its Affiliates Control that are necessary or
useful for the Manufacture or Commercialization of the Products in the Territory for the duration of the term of this Agreement.
As of the Effective Date, to Company’s knowledge, all of the Licensed IP and the Licensed Trademarks are valid and enforceable.

 

7.5.2.       Company
is, and shall remain for the Term of this Agreement, the sole and exclusive owner of the entire right, title and interest in and
to the Licensed IP and the Licensed Trademarks.

 

    	Page 27
	 

     

    

 

 

7.5.3.       Company
has, and shall continue to have for the Term of this Agreement, the right to the Licensed IP and the Licensed Trademarks to grant
the licenses to USWM that are granted hereunder.

 

7.5.4.       Company
has not granted, and will not grant during the Term, to any Third Party any license, lien, option, encumbrance, or other contingent
or non-contingent right, title or interest in or to the Licensed IP or Licensed Trademark(s) (each, an “Encumbrance”)
that conflicts with the licenses granted to USWM hereunder or would materially impair USWM’s rights hereunder regarding the
Licensed IP or Licensed Trademark(s). For avoidance of doubt, Company may grant an Encumbrance in or to the Licensed IP or Licensed
Trademark(s) to a lender or other similar Third Party (in either case, solely to the extent such Third Party is not in the business
of developing or commercializing pharmaceutical products) provided that such Encumbrance does not materially impair USWM’s
rights hereunder regarding the Licensed IP or Licensed Trademark(s).

 

7.5.5.       As
of the Effective Date, Company has not received any notice that has not been resolved from a Third Party alleging that (i) the
practice of the Licensed IP or the Licensed Trademark(s) infringes or may infringe such Third Party’s intellectual property
right, or (ii) Development or Manufacturing of the Products by Company infringes or misappropriates the intellectual property rights
of any Third Party.

 

7.5.6.       As
of the Effective Date, to Company’s knowledge there is no actual or threatened infringement by a Third Party of any of the
Licensed IP or the Licensed Trademark(s) licensed to USWM hereunder.

 

7.5.7.       As
of the Effective Date, there is no settled, pending, or unresolved action, claim, demand, suit, proceeding, arbitration, grievance,
citation, summons, subpoena, inquiry or investigation of any nature, civil, criminal, regulatory or otherwise, in law or in equity,
pending or, to the best of Company’s knowledge, threatened against Company in connection with the Products or any of the
Licensed IP or Licensed Trademark(s) licensed to USWM hereunder, in each of the above cases which would reasonably be expected
to impair, restrict or prohibit the ability of USWM or Company to perform its obligations and enjoy the benefits of this Agreement.

 

7.5.8.       Company
has complied in all material respects with all Applicable Laws in connection with the prosecution of the Licensed IP, including
any disclosure requirements of the United States Patent and Trademark Office, and has timely paid all filing and renewal fees payable
with respect thereto.

 

7.5.9.       Company
is in material compliance with all agreements (i) with the Product Manufacturers, and (ii) with all other Third Parties applicable
to this Agreement. To the best of its knowledge, Company is not aware of any threatened material breach or termination to any of
the foregoing contracts.

 

7.5.10.     Each
Product delivered to USWM will be conveyed with good title, free and clear of all encumbrances.

 

    	Page 28
	 

     

    

 

 

7.5.11.     As
of the Effective Date, the estimated Supply Prices for each Product set forth in Schedule E are accurate and otherwise consistent
with the terms and conditions of Company’s agreements (i) with the Product Manufacturers, and (ii) with all other applicable
Third Parties.

 

7.6.         Additional
USWM Representations and Warranties.

 

7.6.1.       In
the performance of its obligations and activities under or contemplated by this Agreement, USWM shall comply and shall use [***]
to cause its employees and contractors and those of its Affiliates that are engaged in Commercialization of the Product in the
Territory (but not any other Affiliates of USWM) to comply with all Applicable Laws, including without limitation Applicable Laws
regarding corruption, bribery, kickbacks, ethical business conduct, fraud and money laundering.

 

7.7.         Disclaimer.
Except as expressly set forth in this Agreement, neither Party makes any warranties, express
or implied, including, without limitation, as to DESIGN, merchantability, fitness for a particular purpose, OR NON-INFRINGEMENT
OF INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES, ARISING FROM A COURSE OF DEALING, USAGE OR TRADE PRACTICES, or
any other matter concerning the commercial utility of the Products.

 

8.            INDEMNIFICATION;
LIABILITY.

 

8.1.         Company
Indemnification. Company shall indemnify, defend and hold USWM Indemnified Parties harmless from and against any Liability
paid or payable by USWM Indemnified Parties to a Third Party as a result of any Claim that results from, arises out of or is based
upon: (a) the inaccuracy or breach of any of the representations, warranties, covenants, obligations or agreements made by Company
in this Agreement, the Pharmacovigilance Agreement, or the Quality Agreement; (b) the negligence or willful misconduct of Company,
its Affiliates, officers, directors, agents, and employees relating to this Agreement; (c) the Development, Processing or Manufacturing
of the Products by or on behalf of Company pursuant to this Agreement; (d) any Product Liability Claim involving a failure to warn
claim, a Product manufacturing defect (i.e., non-Conforming Product) or a Product design defect; (e) any failure to supply penalties
incurred by USWM from any of USWM’s customers as a result of Company’s failure to provide the Products in accordance
with this Agreement unless caused by any negligent action or omission of USWM, (f) any infringement of the Intellectual Property
Rights of a Third Party; in each case, except to the extent to, or for matters for, which USWM would be required to indemnify Company
Indemnified Parties under Section 8.2, or (g) the conduct or operation of the Business or other ownership, use or license of the
Products before, or in respect of periods preceding, the Effective Date.

 

8.2.         USWM
Indemnification. USWM shall indemnify, defend and hold Company Indemnified Parties harmless from and against any Liability
paid or payable by Company Indemnified Parties to a Third Party as a result of any Claim that results from, arises out of or is
based upon: (a) the inaccuracy or breach of any of the representations, warranties, covenants, obligations or agreements made by
USWM in this Agreement; (b) the negligence or willful misconduct of USWM, its Affiliates, officers, directors, agents and employees
relating to this Agreement; or (c) the Commercialization of the Products by or on behalf of USWM or its Affiliates; in each case,
except to the extent to, or for matters for, which Company would be required to indemnify USWM Indemnified Parties under Section
8.1.

 

    	Page 29
	 

     

    

 

 

8.3.         Prompt
Notice Required. A Company Indemnified Party or USWM Indemnified Party, as applicable (the “Indemnitee”)
seeking indemnification pursuant to this Section 8 shall give prompt notice (but in any event no later than as reasonably practicable
after such Indemnitee becomes aware of such Third Party claim in order to allow the Indemnitor to attempt to resolve the claim
with the respective Third Party) of the matter which may give rise to such claim to the Party against whom indemnification may
be sought (the “Indemnitor”); provided, however, that the failure to notify the Indemnitor shall not relieve
it from any liability that it may have to the Indemnitee otherwise unless the Indemnitor demonstrates that the defense of the underlying
Claim has been materially prejudiced by such failure to provide timely notice. Such notice shall request indemnification and describe
the Liability and Claim giving rise to the request for indemnification, and provide relevant details thereof. The Indemnitor shall
notify the Indemnitee no later than thirty (30) days from such notice of its intention to assume the defense of any such Claim.
If the Indemnitor fails to give the Indemnitee notice of its intention to defend any such Claim as provided in this Section 8.3,
the Indemnitee involved shall have the right to assume the defense thereof with counsel of its choice, at the Indemnitor’s
expense, and defend, settle or otherwise dispose of such Claim with the consent of the Indemnitor, not to be unreasonably denied,
withheld, conditioned or delayed.

 

8.4.         Indemnitor
May Settle. The Indemnitor shall at its expense, have the right to control, through counsel satisfactory to the Indemnitee
(such satisfaction of Indemnitee shall not be unreasonably denied, withheld, conditioned or delayed), any Claim or Liability which
is or may be brought in connection with all matters for which indemnification is provided hereunder, including without limitation
the right to settle or defend. In such event the Indemnitee of the Claim or Liability in question and any successor thereto shall
permit Indemnitor’s counsel and independent auditors, to the extent relevant, full and free access to its Books and Records
and otherwise fully cooperate with the Indemnitor in connection with such Claim or Liability; provided, however, that (i) the Indemnitee
shall have the right fully to participate in such defense at its own expense; (ii) the Indemnitor’s counsel and independent
auditors shall not disclose any Confidential Information of the Indemnitee to the Indemnitor without the Indemnitee’s consent,
except as permitted pursuant to Section 10.2; and (iii) access shall only be given to the Books and Records that are relevant to
the Claim or Liability at issue. Any defense arguments and proceedings by the Indemnitor of any such actions shall not be deemed
a waiver by the Indemnitee of its right to assert a claim with respect to the responsibility of the Indemnitor with respect to
the Claim or Liability in question. The Indemnitor shall have the right to settle or compromise any Claim against the Indemnitee
without the consent of the Indemnitee provided that the terms thereof: (a) provide for the unconditional release of Claims and/or
Liabilities against the Indemnitee; (b) require the payment of compensatory monetary damages by Indemnitor only; and (c) expressly
state that neither the fact of settlement nor the settlement agreement shall constitute, or be construed or interpreted as, an
admission by the Indemnitee of any issue, fact, allegation or any other aspect of the Claim being settled. In all other cases,
the Indemnitee and Indemnitor must agree to enter into any proposed settlement, which shall not be unreasonably denied, withheld,
conditioned or delayed. No Indemnitee shall pay or voluntarily permit the determination of any Liability which is subject to any
such Claim while the Indemnitor is negotiating the settlement thereof or contesting the matter, except with the prior written consent
of the Indemnitor, which consent shall not be unreasonably denied, withheld, conditioned or delayed.

 

    	Page 30
	 

     

    

 

 

8.5.         Assistance.
Each Party shall use Commercially Reasonable Efforts to provide all relevant information in its possession and reasonable assistance
to the other Party as necessary to enable the other Party to defend any Claim. Nothing herein shall prevent the Indemnitee from
retaining counsel of its choice, at such Indemnitee’s expense, to monitor the defense, trial, or settlement of a Claim, and
the Indemnitor and its counsel shall reasonably cooperate with such Indemnitee counsel.

 

8.6.         Limitation
of Liability. To the FULLEST extent permitted
by Applicable Law, neither Party shall be LIABLE TO the other Party OR ANY OTHER PERSON FOR any special, incidental, consequential
or punitive damages in connection with this Agreement except to the extent that a Party is solely seeking reimbursement for such
damages paid to a Third Party and such reimbursement is covered by the indemnification provisions of this Agreement; and provided
that this Section 8.6 shall not be construed to limit a Party’s right to special, incidental or consequential damages for
the other Party’s breach of Section 10.

 

9.            INSURANCE.

 

9.1.         Parties’
Insurance. Each Party, at its sole cost, at all times during [***], maintain the insurance coverages with the minimum limits
as set forth below. Notwithstanding the foregoing, to the extent USWM [***] USWM shall use [***]. Insurance shall be purchased
from insurance companies licensed to do business within the state or country where any Manufacturing work is being performed and
rated A.M. Best A-VIII or better. It is also understood and agreed that any deductibles associated with the insurance coverage
set forth below shall be assumed by the Party at its sole cost. Within [***], each Party shall provide the other Party with proof
of insurance demonstrating its compliance with the obligations of this Section 9.

 

		a.	Statutory Workers’ Compensation insurance, including occupational disease, as required
by the State(s) in which workers are located;

 

		b.	Employer’s Liability insurance in the amount of [***];

 

		c.	Commercial General Liability insurance, including Contractual Liability, with a combined
single limit of not less than [***], and [***]; and

 

		d.	Product Liability Insurance, including Products/Completed Operations insurance, of
not less than [***], and [***] in the aggregate.

 

    	Page 31
	 

     

    

 

 

9.1.1.       All
insurance coverage required of Parties will be primary and not concurrent or excess over any insurance or self-insurance program
carried by a Party, and will have no recourse to any self-insured program or insurance program carried by a Party.

 

9.1.2.       By
requiring Parties to maintain insurance, neither Party represents that coverage and limits required will be adequate to fund all
Liabilities for which Parties may be liable. The limits of insurance coverage shall not affect or limit the liability or indemnity
obligations of the Parties stated elsewhere in this Agreement or as required by Applicable Law.

 

9.1.3.       All
required insurance coverage of Parties will be maintained without interruption during the Term of this Agreement.

 

9.2.        Maintenance
Covenant. Each Party represents, warrants and covenants that nothing has or will be done or be omitted to be done that may
result in any of the said insurance policies being or becoming void, voidable or unenforceable during the Term or any Renewal Term
of this Agreement.

 

10.          CONFIDENTIALITY.

 

10.1.       Obligations.
Each Party acknowledges that it may receive Confidential Information of the other Party in the performance of this Agreement. Each
Party shall safeguard and hold such information received by it from the other Party in confidence by using such reasonable precautions
as it normally takes with its own confidential and proprietary information, but in no event less than a reasonable degree of care,
and each Party shall limit disclosure of the furnishing Party’s information to those employees and consultants of the receiving
Party and its Affiliates who are informed of and understand the confidential nature thereof and are bound by non-disclosure and
non-use obligations no less restrictive than those set forth in this Agreement. To the extent that such employees or consultants
take an action, or fail to take an action, that would constitute a breach of such confidentiality or non-use obligations by such
employee or contractor (as if such employee or contractor were a party to this Agreement), it will constitute a breach of such
obligations as if a Party had taken, or failed to take, such action itself. Each receiving Party shall not, directly or indirectly,
disclose, publish or use for the benefit of any Third Party or itself, except in exercising its rights and carrying out its duties
hereunder or as otherwise provided in this Section 10, any Confidential Information of the other Party, without first having obtained
the furnishing Party’s prior written consent to such disclosure or use. This restriction shall not apply to any information
within the following categories: (i) information that is known to the receiving Party or its Affiliates prior to the time of disclosure
to it, to the extent evidenced by written records or other competent proof; (ii) information that is independently developed by
employees, agents, or independent contractors of the receiving Party or its Affiliates without reference to or reliance upon the
information furnished by the disclosing Party, as evidenced by written records or other competent proof; (iii) information disclosed
at any time to the receiving Party or its Affiliates by a Third Party that has a right to make such disclosure; or (iv) any other
information that is or becomes part of the public domain through no fault or negligence of the receiving Party.

 

    	Page 32
	 

     

    

 

 

10.2.       Required
Disclosures. The receiving Party shall also be entitled to disclose the other Party’s Confidential Information (i) that
is required to be disclosed in compliance with Applicable Law or regulations (including, without limitation, to comply with SEC,
NASDAQ, NYSE or similar stock exchange disclosure requirements) or by order of any governmental body or a court of competent jurisdiction,
or (ii) as may be necessary or appropriate in connection with the enforcement of this Agreement; provided, however, that, in both
cases, the Party disclosing such information shall, if practicable, promptly notify the other Party in advance of any required
or necessary disclosure and shall use Commercially Reasonable Efforts to obtain confidential treatment of such information by the
agency or court or other disclosee, and that, in the case of disclosures under (i), shall (a) provide the other Party with prompt
prior notice of the proposed disclosure such that the other Party may seek a protective order or other appropriate remedy, (b)
provide the other Party with a copy of the proposed disclosure in sufficient time to allow reasonable opportunity to comment thereon,
and (c) disclose only that portion of the Confidential Information that, in the opinion of its legal counsel, must be disclosed
pursuant to Applicable Law.

 

10.3.       Use
of Information. Each Party shall only use, and direct each of its Affiliates to only use, any Confidential Information obtained
by it from the other Party or their respective Affiliates, pursuant to this Agreement or otherwise, solely in connection with the
transactions contemplated hereby.

 

10.4.       Return
of Information. Upon the earlier of expiration or termination of this Agreement, the receiving Party shall, if requested by
the disclosing Party, return or destroy all Confidential Information of the disclosing Party including copies and extracts thereof;
provided, that the receiving Party shall not be required to return or destroy any electronic copy of Confidential Information created
pursuant to its standard electronic backup and archival procedures. Notwithstanding the foregoing, the receiving Party may retain
one copy of any Confidential Information of the disclosing Party to the extent required to defend or maintain any litigation relating
to this Agreement, comply with legal or regulatory requirements or established document retention policies, or to demonstrate compliance
with this Agreement. Notwithstanding the return or destruction of the Confidential Information (or the retention of any Confidential
Information pursuant to the preceding sentence) the Parties shall continue to be bound by its obligations of confidentiality and
non-use hereunder. Each Party’s obligations of confidentiality and non-use shall extend during the Term and for a period
of [***] from the expiration or termination of this Agreement.

 

10.5.       Publicity.
The Parties may mutually agree to issue a joint press release substantially, in a form agreed by the Parties, as of the Effective
Date or as promptly as practicable following the Effective Date. Each agrees to consult with the other Party reasonably and in
good faith with respect to the text and timing of any publicity, news release or public announcement, written or oral, whether
to the public, the press, stockholders or otherwise, referring to the terms or existence of this Agreement, the subject matter
to which it relates, the performance under it or any of its specific terms and conditions, prior to any such disclosure. Either
Party may make, such reasonable announcements or disclosures to securities exchanges or other applicable agencies as it determines
(based on advice of the legal counsel for the Party making such announcement) are required by Applicable Law, including United
States securities laws, rules or regulations, or market disclosure. Each Party shall provide the other Party with advance notice
of legally required disclosures and shall reasonably consider input from the other Party concerning such required disclosures.
Each Party may make any public statement in response to questions by the press, analysts, investors or those attending industry
conferences or financial analyst calls, or issue press releases, so long as any such public statement or press release is not inconsistent
with prior public disclosures or public statements made in accordance with this Section 10.5 and which do not reveal non-public
information about the other Party.

 

    	Page 33
	 

     

    

 

 

10.6.       Filing
of this Agreement. The Parties will coordinate in advance with each other in connection with the filing of this Agreement (including
redaction of certain provisions of this Agreement) with the U.S. Securities and Exchange Commission or any stock exchange or governmental
authority on which securities issued by a Party or its Affiliate are traded, and each Party will use reasonable efforts to seek
confidential treatment for the terms proposed to be redacted; provided that, each Party will ultimately retain control over what
information to disclose to the U.S. Securities and Exchange Commission or any stock exchange or other governmental authority, as
the case may be, and provided further that the Parties will use their reasonable efforts to file redacted versions with any governing
bodies which are consistent with redacted versions previously filed with any other governing bodies. Other than such obligation,
neither Party (nor its Affiliates) will be obligated to consult with or obtain approval from the other Party with respect to any
filings to the U.S. Securities and Exchange Commission or any stock exchange or other governmental authority on which securities
issued by a Party or its Affiliate are traded.

 

10.7.       Prior
Non-Disclosure Agreement. As of the Effective Date, the terms of this Section 10 shall supersede any prior non-disclosure,
secrecy or confidentiality agreement between the Parties (or their Affiliates) dealing with the subject of this Agreement. Any
information disclosed pursuant to any such prior agreement shall be deemed Confidential Information for purposes of this Agreement.

 

10.8.       Equitable
Relief. Given the nature of the Confidential Information and the irreparable harm that a Party may suffer upon unauthorized
disclosure, use or transfer of its Confidential Information to any Third Party, the Parties agree that monetary damages may not
be a sufficient remedy for any breach of this Section 10. In addition to all other remedies, a Party shall be entitled to seek
specific performance and injunctive and other equitable relief as a remedy for any breach or threatened breach of this Section
10.

 

11.         TERM
AND TERMINATIOn.

 

11.1.       Term.
The term of this Agreement shall begin on the Effective Date and, unless otherwise terminated as permitted under this Agreement,
shall continue for a period of ten (10) years from the Launch of the first Product in the Territory pursuant to this Agreement
(the “Initial Term”). This Agreement shall thereafter be automatically renewed for consecutive five (5) year
renewal terms (each a “Renewal Term”) unless this Agreement is otherwise (i) terminated by mutual prior written
agreement by Parties (either with respect to the ZIMHI Product or the SYMJEPI Product individually, or both Products collectively),
or (ii) terminated by a Party as permitted under this Agreement. The “Term” means the Initial Term and, if applicable,
the Renewal Term.

 

    	Page 34
	 

     

    

 

 

11.2.       Termination.

 

11.2.1.    Termination
for Cause. Subject to the terms of this Section 11.2.1, a Party may terminate this Agreement for any breach of a material provision
of this Agreement by the other Party [***] in the case of payment breach) after written notice to the other Party containing details
of such breach if the breach remains uncured at the end of such notice period. Notwithstanding the foregoing, the Parties agree
that the [***] notice and cure period herein may be extended if the breaching Party is [***] to cure the specified breach. With
respect to a default or breach of this Agreement, failure of a Party to provide notice to the defaulting or breaching Party as
required by this Section 11.2.1 shall not constitute a waiver of the right to give such notice with respect to any subsequent default
or breach. A Party may terminate this Agreement pursuant to this Section 11.2.1 (i) with respect to the ZIMHI Product or the SYMJEPI
Product individually to the extent the uncured breach arises pursuant to an obligation concerning a Product individually, or (ii)
with respect to both Products collectively to the extent the uncured breach arises pursuant to obligations concerning both Products
collectively.

 

11.2.2.    USWM
Termination.

 

a.       Failure
to Supply. If at any time during the Term, (a) Company is unable to deliver Product pursuant to a Firm Order for a period longer
than [***] after the applicable delivery date set forth in the respective Firm Order for causes within Company’s control,
or (b) if the Company is unable to supply, or arrange to make available for shipment the Launch Quantity within [***] of the Regulatory
Approval for causes within Company’s control; then, in either case (each such occurrence a “Failure to Supply”),
USWM may, upon [***] prior written notice to Company that a Failure to Supply has occurred, request in such notice that Company
exercise, and Company shall, at Company’s sole cost and expense, [***] to (i) evaluate, contract, and qualify a mutually
agreeable alternate manufacturing facility to manufacture and supply all of USWM’s requirements of Product(s) in the Territory,
(ii) transfer sufficient know-how to the alternate manufacturing facility in order to enable the facility to manufacture the Product(s)
in accordance with the terms of this Agreement, and (iii) ensure that the alternate manufacturing facility is contractually obligated
to use commercially reasonable efforts to be approved by the applicable Regulatory Authority to manufacture commercial quantities
of the Product(s) and is brought up to production readiness as soon as reasonably possible following USWM’s written notice
specified above. In the event an alternate manufacturing facility is utilized to supply Products under this Agreement, such facility
shall be deemed a “Manufacturing Facility” for purposes of this Agreement. Subject to Company [***], the Parties may
mutually agree to terminate this Agreement (either with respect to the ZIMHI Product or the SYMJEPI Product individually, or both
Products collectively). Notwithstanding anything in this Section 11.2.2(a), in the event that a Failure to Supply arises by the
willful act or omission of Company (and not for other reasons including without limitation acts or omissions of third parties beyond
the reasonable control of Company or acts or omissions relating to [***] taken in good faith by Company), USWM may, in its sole
discretion, elect to terminate this Agreement (either with respect to the ZIMHI Product or the SYMJEPI Product individually, or
both Products collectively, as the case may be) at the end of such [***] notice period, and Company shall pay to USWM within [***]
of the [***] an amount equal to [***]. In the event that either (i) Company fails to [***], or (ii) supply of the affected Product(s)
fails to resume within [***] from [***], USWM may, in its sole discretion, elect to terminate this Agreement (either with respect
to the ZIMHI Product or the SYMJEPI Product individually, or both Products collectively) unless supply of the affected Product(s)
resumes during such [***] notice period and, in the event that USWM elects to terminate this Agreement (either with respect to
the ZIMHI Product or the SYMJEPI Product individually, or both Products collectively, as the case may be) Company shall pay to
USWM within [***] of the effective date of termination an amount equal to [***] of (a) [***], or (b) [***]. For purposes of clarity,
the remedies available to USWM pursuant to this Section 11.2.2(a) are in addition to any other remedies available to USWM under
this Agreement, including without limitation, USWM’s indemnification rights pursuant to Section 8.1. Notwithstanding the
foregoing, USWM shall not be entitled to exercise the remedies in this Section 11.2.2(a) upon a Failure to Supply as a result of
a Force Majeure event in accordance with Section 12.10.

 

    	Page 35
	 

     

    

 

 

b.       Infringement
Action. From the Effective Date through a period of [***] following [***], USWM may, upon [***] prior written notice to Company,
terminate this Agreement (either with respect to the ZIMHI Product or the SYMJEPI Product individually, or both Products collectively,
as the case may be) if [***] that prevents either (i) [***], or (ii) [***]. In the event that USWM terminates this Agreement (either
with respect to the ZIMHI Product or the SYMJEPI Product individually, or both Products collectively, as the case may be) pursuant
to this Section 11.2.2(b), Company shall pay to USWM within [***] of [***] an amount equal to [***] plus the greater of (i) [***],
or (ii) [***]. For purposes of this Agreement, “Infringement Action” any claim of infringement or potential
infringement of Third Party intellectual property rights in connection with the marketing, development, manufacture, production,
use, importation, offer for sale, or sale of the Products in the Territory.

 

c.       Regulatory
Approval. If, as it relates to the ZIMHI Product, Regulatory Approval has not been achieved within [***], USWM, in its sole
discretion, may elect to either (i) upon [***] prior written notice to Company, terminate this Agreement only with respect to the
ZIMHI Product individually, or (ii) [***].

 

11.2.3.    Termination
by the Company.

 

a.       Failure
to Launch. Subject to the terms of this Section 11.2.3(a), upon [***] prior written notice to USWM, Company shall have, at
its sole discretion, the right to terminate this Agreement if within [***] (or such longer period as agreed in writing by the Parties)
after both (i) [***], and (ii) [***], USWM fails to Launch the Product in the Territory, provided such failure is for causes within
USWM’s control. Company may terminate this Agreement pursuant to this Section 11.2.3(a) only with respect to the ZIMHI Product
or the SYMJEPI Product individually to the extent USWM fails to Launch each of the Products individually on the terms and subject
to the conditions otherwise set forth in this Section 11.2.3(a).

 

b.       Commercial
Efforts. Subject to the terms of this Section 11.2.3(b), upon [***] prior written notice to USWM, Company may terminate this
Agreement in part or in its entirety if (i) USWM fails to [***] for [***], and (ii) such failure by USWM remains uncured at the
end of such notice period; provided such failure is for causes within USWM’s reasonable control. Notwithstanding the foregoing,
the Parties agree that the [***] notice and cure period herein may be extended if USWM is [***] to cure the specified failure.
Company may terminate this Agreement pursuant to this Section 11.2.3(b) only with respect to the ZIMHI Product or the SYMJEPI Product
individually to the extent USWM fails to meet [***] for [***] as such [***] are determined with respect to each of the Products
individually, and on the terms and subject to the conditions otherwise set forth in this Section 11.2.3(b).

 

    	Page 36
	 

     

    

 

 

11.2.4.    Bankruptcy.
To the extent permitted under Applicable Law, a Party may terminate this Agreement (either with respect to the ZIMHI Product or
the SYMJEPI Product individually, or both Products collectively) effective immediately with written notice if the other Party shall
be adjudicated bankrupt, shall be dissolved or shall have a receiver appointed for substantially all of its property. All rights
and licenses granted by Company under or pursuant to this Agreement are, and shall otherwise be deemed to be, for purposes of Section
365(n) of the Bankruptcy Code, rights and licenses to “intellectual property” as such term is used in, and interpreted
under Section 101(35A) of the Bankruptcy Code. The Parties shall retain and may fully exercise all of their respective rights,
elections, and protections under the Bankruptcy Code, and all other bankruptcy, insolvency, and similar laws with respect to this
Agreement and the subject matter hereof. Without limiting the generality of the foregoing, Company acknowledges and agrees that,
if Company or its estate shall become subject to any bankruptcy or similar proceeding, (i) subject to USWM’s rights of election
under Section 365(n) of the Bankruptcy Code, all rights, licenses, and privileges granted to USWM under this Agreement will continue
subject to the respective terms and conditions hereof, and will not be affected, even by Company’s rejection of this Agreement,
(ii) USWM shall further be entitled to a complete duplicate of (or complete access to, as appropriate) any and all such intellectual
property and embodiments of intellectual property, which if not already in USWM’s possession, shall be promptly delivered
to USWM or its designee, and (iii) Company shall undertake [***] to ensure USWM’s access to Company’s contracts with
the Product Manufacturers, in both instances of (ii) and (iii) to the extent needed to allow USWM to make or have made and continue
to Commercialize any Product under this Agreement, and such, if not already in its possession, shall be promptly delivered to USWM
by Company, unless the Company elects to continue, and does in fact continue to perform all of its obligations under this Agreement.
All [***] incurred by USWM to [***] may be deducted by USWM from [***]. Notwithstanding the foregoing, if USWM (or any administrator,
receiver, liquidator, trustee appointed over all or any parts of its assets, or similar entity) selects to continue, and does in
fact continue to perform all of its obligations under this Agreement, then Company shall not be entitled to terminate this Agreement
pursuant to this Section 11.2.4.

 

11.2.5.    Effects
of Termination.

 

a.       Except
(i) to the extent this Agreement is terminated solely with respect to a Product individually (in which case the Parties’
rights and obligations pursuant to this Agreement with regard to such non-terminated Product shall be unaffected by this Section
11.2.5(c)), and (ii) as expressly set forth in this Agreement, upon expiration or termination of this Agreement for any reason,
neither Party shall have any obligation to make any payments to the other, except for amounts accrued prior to expiration or termination,
including any owed and payable outstanding liabilities.

 

b.       Except
to the extent this Agreement is terminated solely with respect to a Product individually (in which case the Parties’ rights
and obligations pursuant to this Agreement with regard to such non-terminated Product shall be unaffected by this Section 11.2.5(b)),
in the event of expiration or termination of this Agreement by (i) Company pursuant to Section 11.2.1 (Termination for Cause),
Section 11.2.3(a) (Failure to Launch), Section 11.2.3(b) (Commercial Efforts), or Section 11.2.4 (Bankruptcy), or (ii) USWM pursuant
to Section 11.2.1 (Termination for Cause), Section 11.2.2(a) (Failure to Supply), Section 11.2.2(b) (Infringement Action), or Section
11.2.4 (Bankruptcy), all licenses and rights granted by Company to USWM will terminate, and each Party will promptly return to
the other Party all materials and records in its possession or control containing Confidential Information of the other Party.

 

    	Page 37
	 

     

    

 

 

c.       Except
to the extent this Agreement is terminated solely with respect to a Product individually (in which case the Parties’ rights
and obligations pursuant to this Agreement with regard to such non-terminated Product shall be unaffected by this Section 11.2.5(c)),
in the event of early termination of this Agreement for any reason other than termination by Company pursuant to Section 11.2.1
(Termination for Cause), Section 11.2.3(a) (Failure to Launch) or Section 11.2.4 (Bankruptcy), USWM and its Affiliates shall have
the right, in USWM’s sole discretion, to continue, to the extent that USWM and its Affiliates continue to have Product inventory,
to fulfill orders received from customers for the Products in the Territory until up to [***] after the effective date of termination
of this Agreement. For Product sold by USWM or its Affiliates after the effective date of termination, USWM shall continue to make
payments to Company in accordance with Section 6, as applicable.

 

11.2.6.     Non-Exclusive
Remedy. Subject to Section 8.6, the termination of this Agreement shall be in addition to, and shall not prejudice, the Parties’
remedies at law or in equity, including, without limitation, the Parties’ ability to receive legal damages and/or equitable
relief with respect to any breach of this Agreement, regardless of whether or not such breach was the reason for the termination.

 

12.         GENERAL.

 

12.1.       Interpretation.
The headings of each Article and Section in this Agreement have been inserted for convenience of reference only and are not intended
to limit or expand on the meaning of the language contained in the particular Article or Section. The definitions of the terms
herein apply equally to the singular and plural forms of the terms defined. Whenever the context may require, any pronoun will
include the corresponding masculine, feminine and neuter forms. The words “include”, “includes” and “including”
shall be deemed to always be followed by the phrase “without limitation.” Unless the context requires otherwise, (a)
any definition of or reference to any agreement, instrument or other document herein will be construed as referring to such agreement,
instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such
amendments, supplements or modifications set forth herein or therein), (b) any reference to any laws herein will be construed as
referring to such laws and any rules or regulations promulgated thereunder as from time to time enacted, repealed or amended, (c)
any reference herein to any person will be construed to include the person’s successors and assigns, (d) the words “herein”,
“hereof” and “hereunder”, and words of similar import, will be construed to refer to this Agreement in
its entirety and not to any particular provision hereof, (e) any reference herein to the words “mutually agree” or
“mutual written agreement” will not impose any obligation on either Party to agree to any terms relating thereto or
to engage in discussions relating to such terms except as such Party may determine in such Party’s sole discretion, except
as expressly provided in this Agreement, (f) as applied to a Party, the word “will” shall be construed to have the
same meaning and effect as the word “shall,” and (g) all references herein without a reference to any other agreement
to Articles, Sections, or Exhibits will be construed to refer to Articles, Sections, and Exhibits of or to this Agreement.

 

    	Page 38
	 

     

    

 

 

12.2.       Exclusivity.
During the Term of this Agreement, except (i) as contemplated by this Agreement, including but not limited to (X) [***] and (Y)
[***], (ii) as contemplated under Other Agreements, or (ii) upon the prior written consent of the other Party, the Company agrees
not to, directly or indirectly, and [***].

 

12.3.       Informal
Dispute Resolution. Unless otherwise expressly provided for herein, any disputes arising out of or in connection with this
Agreement (“Dispute”) shall be identified in writing and presented to the other Party. Within [***] after delivery
of such notice of dispute, the USWM Executive Officer and the Company Executive Officer shall meet at a mutually acceptable time
and place, and thereafter as often as they reasonably deem necessary, to attempt to resolve the dispute in good faith. All reasonable
requests for information made by one Party to another shall be honored. All negotiations pursuant to this clause are confidential
and shall be treated as compromise and settlement negotiations for purposes of applicable rules of evidence. If such Executive
Officers cannot resolve such dispute within [***] after such meeting, then, subject to Section 12.4, each Party reserves its right
to any and all remedies available under law or equity with respect to any other dispute.

 

12.4.       Jurisdiction.
Any Dispute that is not resolved under Section 12.3 within the time periods described in such section shall be resolved by final
and binding arbitration before a panel of one arbitrator with relevant industry experience. The arbitration proceeding shall be
administered in accordance with the Commercial Arbitration Rules of the American Arbitration Association (“AAA”),
and the panel of arbitrators shall be selected in accordance with such rules. The arbitration and all associated discovery proceedings
and communications shall be conducted in English, and the arbitration shall be held in a reasonable location to be selected by
the Party against whom arbitration is compelled. The location selected by such Party shall not be located in a state in which the
respective selecting Party is domiciled. The arbitrator shall, reasonably promptly after the conclusion of the arbitration hearing,
issue a written award and statement of decision describing the essential findings and conclusions on which the award is based,
including the calculation of any damages awarded. The decision or award rendered by the arbitrator shall be final and non-appealable,
and judgment may be entered upon it in any court of competent jurisdiction. Either Party may apply for interim injunctive relief
with the arbitrator until the arbitration award is rendered or the controversy is otherwise resolved. The arbitrator shall be authorized
to award compensatory damages, but shall not be authorized (i) to award noneconomic damages, (ii) to award punitive damages or
any other damages expressly excluded under this Agreement, or (iii) to reform, modify or materially change this Agreement or any
other agreements contemplated hereunder; provided, however, that the damage limitations described in subsections (i) and (ii) of
this sentence will not apply if such damages are statutorily imposed. Each Party shall bear its own attorneys’ fees, costs,
and disbursements arising out of the arbitration, and shall pay an equal share of the fees and costs of AAA and the arbitrator;
provided, however, the arbitrator shall be authorized to determine whether a Party is the prevailing Party, and at the arbitrator’s
discretion, to award to that prevailing Party reimbursement for its reasonable attorneys’ fees, costs and disbursements (including,
for example, expert witness fees and expenses, photocopy charges, travel expenses, etc.), and/or the fees and costs of the AAA
and the arbitrator. Subject to the foregoing provisions, the Company and USWM agree to irrevocably submit to the jurisdiction of
the federal and state courts for the judicial district in which the underlying arbitration occurred, for the purposes of any suit,
action or other proceeding arising out of this Agreement or any transaction contemplated hereby, and agrees that services of any
process may be made in the manner provided in this Agreement for delivery of notices. Each Party irrevocably and unconditionally
waives any objection to the laying of venue of any action, suit or proceeding arising out of this Agreement or the transactions
contemplated hereby in such courts. Each Party hereto agrees that any such proceeding shall be conducted solely in the English
language.

 

    	Page 39
	 

     

    

 

 

12.5.       Waiver
of Jury Trial. EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO INVOLVE
COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE IT HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL
BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT. EACH PARTY CERTIFIES
AND ACKNOWLEDGES THAT (I) NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT
SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE EITHER OF SUCH WAIVERS; (II) IT UNDERSTANDS AND HAS CONSIDERED
THE IMPLICATIONS OF SUCH WAIVERS; (III) IT MAKES SUCH WAIVERS VOLUNTARILY; AND (IV) IT HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT
BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS CLAUSE 12.5.

 

12.6.       Governing
Law. This Agreement and any and all matters arising directly or indirectly herefrom shall be governed by and construed and
enforced in accordance with the internal laws of the State of Delaware, U.S.A. applicable to agreements made and to be performed
entirely in such state, without giving effect to the conflict of law principles thereof. The Parties expressly agree that the United
Nations Convention on Contracts for the International Sale of Goods shall not apply to this Agreement or any Party’s performance
hereunder.

 

12.7.       Remedies.
Except as otherwise provided herein, any and all other remedies herein expressly conferred upon a Party will be deemed cumulative
with and not exclusive of any other remedy conferred hereby, or by law or equity upon such Party, and the exercise by a Party of
any one (1) remedy will not preclude the exercise of any other remedy, provided, that a party shall not be entitled to more than
one recovery, without duplication, for the same liability, loss or damage.

 

    	Page 40
	 

     

    

 

 

12.8.       Convictions,
Exclusion, Debarment, Etc. Neither Party nor any person employed by or under contract to such Party now or in the future in
connection with any activities contemplated by this Agreement (i) has been convicted of an offense related to any Federal or State
healthcare program, including (but not limited to) those within the scope of 42 U.S.C. § 1320a-7(a); (ii) has been excluded,
suspended or is otherwise ineligible for Federal or State healthcare program participation, including (but not limited to) persons
identified on the General Services Administration’s List of Parties Excluded from Federal Programs or the HHS/OIG List of
Excluded Individuals/Entities; (iii) has been debarred from or under any Federal or State healthcare program (including, but not
limited to debarment under Section 306 of the Federal Food, Drug and Cosmetic Act (21 USC 335a); or (iv) is on any of the FDA Clinical
Investigator enforcement lists, including, but not limited to, the (a) Disqualified/Totally Restricted List, (b) Restricted List,
and (c) Adequate Assurances List. Each Party further agrees that if, at any time after execution of this Agreement, it becomes
aware that it has or any Person who participated, or is participating, in the performance of any activities contemplated by this
Agreement has become or is in the process of being charged, convicted, debarred, excluded, proposed to be excluded, suspended or
otherwise rendered ineligible, or is on an enforcement list, such Party will immediately notify the other Party in writing.

 

12.9.       Assignment
or Transfer of Interest. This Agreement shall be binding upon and inure to the benefit of the successors or permitted assigns
of each of the Parties and may not be assigned or transferred by a Party without the prior written consent of the other, except
that such consent shall not be required on the part of either Party in connection with (i) an assignment or transfer to an Affiliate
of the assigning Party, (ii) a transfer or sale of all or substantially all of the business of that Party to which this Agreement
relates to a Third Party, whether by merger, sale of stock, sale of assets or otherwise, or (iii) a transfer or sale of all or
substantially all of the assets directly related to one (1) or more business units of such Party to a Third Party, whether by merger,
sale of stock, sale of assets or otherwise; provided, however, that in the event of such a transaction (whether this Agreement
is actually assigned or is assumed by the acquiring party by operation of law (e.g., in the context of a reverse triangular
merger)), intellectual property rights of the acquiring party to such transaction (if other than one of the Parties to this Agreement)
shall not be included in the technology licensed hereunder or otherwise subject to this Agreement. Any attempted assignment that
does not comply with the terms of this Section 12.9 shall be void.

 

12.10.     Force
Majeure. No Party shall be liable or responsible to the other Party, nor be deemed to have defaulted under or breached this
Agreement, for any failure or delay in fulfilling or performing any term of this Agreement (except for any obligations to make
payments of amounts invoiced hereunder), when and to the extent such failure is caused by or results from a Force Majeure Event.
The Party claiming a Force Majeure Event shall notify the other Party with notice of the Force Majeure Event as soon as practicable,
which notice shall reasonably identify such obligations under this Agreement and the extent to which performance thereof will be
affected, including the period of time the occurrence is expected to continue. In such event, the Parties shall meet promptly (either
in person or telephonically, as the situation may dictate) to determine an equitable solution to the effects of any such Force
Majeure Event, and the Party affected by the Force Majeure Event shall use all Commercial Reasonable Efforts to minimize the loss
or inconvenience suffered by the Parties.

 

12.11.     Entire
Agreement. This Agreement, including any schedules or exhibits hereto, and the subsequent pharmacovigilance agreement and Quality
Agreement to be executed by the Parties pursuant to this Agreement, contains the entire agreement and understanding between the
Parties relating to the subject matter hereof, and shall supersede all prior or contemporaneous agreements and understandings,
oral or written, relating to the subject matter hereof and any inconsistent terms of any subsequent invoice, purchase order or
similar document. Neither Party shall be liable or bound to the other Party in any manner by any representations, warranties or
covenants relating to such subject matter except as specifically set forth herein.

 

    	Page 41
	 

     

    

 

 

12.12.     Amendments
and Waiver. This Agreement may not be amended except by an instrument in writing signed on behalf of each of the Parties. By
an instrument in writing a Party may waive compliance by another Party with any term or provision of this Agreement that such other
Party was or is obligated to comply with or perform. Any failure of a Party to enforce at any time, or for any time period, any
of the provisions of this Agreement shall not be deemed or construed to be a waiver of such provisions or a waiver of any right
of such Party thereafter to enforce each and every such provision on any succeeding occasion or breach thereof.

 

12.13.     Nature
of Relationship. In making and performing this Agreement, the Parties are acting, and intend to be treated, as independent
entities and nothing contained herein shall be deemed or implied to create an independent contractor, agency, distributorship,
joint venture or partnership relationship among the Parties hereto. Except as otherwise expressly provided herein, no Party may
make any representation, warranty or commitment, whether express or implied, on behalf of or incur any charges or expenses for
the other Party.

 

12.14.     Further
Actions and Documents. Each Party agrees to execute, acknowledge and deliver all such further instruments, and to do all such
further acts, as may be reasonably necessary or appropriate to carry out the intent and purposes of this Agreement.

 

12.15.     Notices.
All notices and other communications required or permitted to be given or made pursuant to this Agreement shall be in writing signed
by the sender and shall be deemed duly given (i) on the date delivered, if personally delivered, (ii) on the date sent by telecopier
or email with automatic confirmation by the transmitting machine showing the proper number of pages were transmitted without error,
(iii) on the Business Day after being sent by FedEx or another recognized overnight mail service which utilizes a written form
of receipt for next day or next Business Day delivery, or (iv) five (5) Business Days after mailing, if mailed by United States
postage-prepaid certified or registered mail, return receipt requested, in each case addressed to the applicable Party at the address
set forth below; provided, that a Party may change its address for receiving notice by the proper giving of notice hereunder:

 

	If
    to USWM:	If
    to Company:	 
	 	 	 
	USWM, LLC

        [***]

        Attn: [***]
	Adamis Pharmaceuticals Corporation

        11682 El Camino Real, Suite 300

        San Diego, CA 92130

        Attn: President & CEO
	 
	Tel: [***]	Tel: (858)
    997-2400	 
	Email:
     [***]	Email:
     [***]	 
	 	 
	With
    a copy to:	 
	 	 
	USWM,
    LLC	 
	[***]	 
	[***]	 
	Attn: [***]	 
	Tel: [***]	 
	Email:
     [***]	 

 

    	Page 42
	 

     

    

 

 

12.16.     Counterparts;
Facsimile/PDF Signature. This Agreement may be executed by the exchange of faxed executed copies, certified electronic signatures
or executed copies delivered by electronic mail in Adobe Portable Document Format or similar format, and any signature transmitted
by such means for the purpose of executing this Agreement shall be deemed an original signature for purposes of this Agreement.
The Parties agree that the electronic signatures appearing on this Agreement are the same as handwritten signatures for the purposes
of validity, enforceability and admissibility pursuant to the Electronic Signatures in Global and National Commerce (ESIGN) Act
of 2000 and Uniform Electronic Transactions Act (UETA) model law or similar applicable laws. This Agreement may be executed in
two or more counterparts, each of which shall be deemed an original as against any Party whose signature appears thereon, but all
of which together shall constitute one and the same instrument.

 

12.17.     Severability.
In the event that any one or more of the provisions contained herein, or the application thereof in any circumstances, is held
invalid, illegal or unenforceable in any respect for any reason, the Parties shall negotiate in good faith with a view to the substitution
therefore of a suitable and equitable solution in order to carry out, so far as may be valid and enforceable, the intent and purpose
of such invalid provision; provided, however, that the validity, legality and enforceability of any such provision in every other
respect and of the remaining provisions contained herein shall not be in any way impaired thereby, it being intended that all of
the rights and privileges of the Parties hereto shall be enforceable to the fullest extent permitted by law.

 

12.18.     Headings.
The captions or headings of the Sections or other subdivisions hereof are inserted only as a matter of convenience or for reference
and are not part of the agreement of the Parties and shall have no effect on the meaning of the provisions hereof. All references
in this Agreement to Sections are to Sections of this Agreement, unless otherwise indicated.

 

12.19.     Expenses.
Each Party will pay all of its own fees and expenses (including all legal, accounting and other advisory fees) incurred in connection
with the negotiation and execution of this Agreement and the arrangements contemplated hereby.

 

12.20.     Third
Party Rights. Nothing in this Agreement will be deemed to create any Third Party beneficiary rights in or on behalf of any
other Person.

 

12.21.     Performance
through Affiliates. Notwithstanding anything to the contrary contained herein, each Party may discharge any obligations and
exercise any right hereunder, or performance hereunder, through any of its Affiliates. Each Party hereby guarantees the performance
by its Affiliates of such Party’s obligations under this Agreement and will cause its Affiliates to comply with the provisions
of this Agreement in connection with such performance.

 

    	Page 43
	 

     

    

 

 

12.22.     Survival.
Expiration or termination of this Agreement shall not relieve the Parties of any rights or obligation accruing prior to such expiration
or termination. In addition, the Parties’ respective rights and obligations set forth in this Section 12.22, Section 5.3,
Sections 6.5 (for [***] following the calendar year in which termination or expiration occurs), 6.6, 7, 9.1.3 (for [***] following
termination or expiration occurs), 11.2.5 and 11.2.6 and Section 1, Sections 8, 10 and 12 (other than 12.1) and any right, obligation,
or required performance of the Parties in this Agreement which, by its express terms or nature and context is intended to survive
termination or expiration of this Agreement, will survive any such termination or expiration.

 

[signature page follows]

 

    	Page 44
	 

     

    

 

IN WITNESS WHEREOF,
each Party is signing this Distribution and Commercialization Agreement on the date stated opposite that Party’s signature.

 

	USWM, LLC	 	 
	 	 	 	 
	By:	     /s/ P. Breckinridge Jones, Sr.	 	Date: ________________
	NAME:      P. Breckinridge Jones, Sr.	 	 
	Title:          CEO	 	 
	 	 	 	 
	ADAMIS PHARMACEUTICALS CORPORATION	 	 
	 	 	 	 
	By:	    /s/ Dennis J. Carlo	 	Date: ________________
	NAME:      Dennis J. Carlo, Ph.D.	 	 
	Title:          President and CEO	 	 

 

[SIGNATURE PAGE TO DISTRIBUTION AND COMMERCIALIZATION AGREEMENT]

 

     

     

    

 

SCHEDULE A

 

Licensed Patents and Licensed Trademarks

 

Licensed Patents:

 

	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]
	[***]	[***]	[***]	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	 	[***]	[***]	[***]

 

Licensed Trademarks:

 

“SYMJEPI” (registered trademark no. 5853281)

 

“ZIMHI” (pending US TM application no. 88281598)

 

Domain Names:

 

SYMJEPI.com

 

ZIMHI.com

 

     

     

    

 

SCHEDULE B

 

Near-Term Milestone Payments and Net
Profit Share

 

Near-Term Milestone Payments

 

	Milestone	Amount Payable
	(i) Within [***]	US$ [***]
	(ii) Within [***]	US$ [***]
	(iii) [***]	US$ [***]

 

Net Profit Share

 

Subject to the terms of the Agreement,
including without limitation, Section 6.2.2 (Net Profit Share Payments) and Section 6.3 (Branded Prescription Drug Fees), USWM
shall pay Company [***] of the Net Profits. USWM shall retain the remaining [***] of the Net Profits.

 

Accelerated Net Profit Share

 

Subject to the terms of the Agreement,
including without limitation, Section 6.2.2 (Net Profit Share Payments), Section 6.2.3 (Accelerated Net Profit Share Payments)
and Section 6.3 (Branded Prescription Drug Fees), in addition to the Net Profit Share Payment USWM shall pay Company an Accelerated
Net Profit Share equal to [***]. After such limit is reached, Net Profit Allocation would revert to the Net Profit Share defined
above. For purposes of clarity, the payment of Accelerated Net Profit Share will end upon the date on which [***].

 

For the avoidance of doubt, the cumulative
total of Near-Term Milestone Payments and Accelerated Net Profit Share Payments shall not exceed a total of US$ [***].

 

     

     

    

 

SCHEDULE C

 

Commercial Milestone Payments and Net
Profit Share

 

Commercial Milestone Payments

 

	Milestones	Amount Payable
	(i)       On [***], upon the initial achievement of [***] (1)	US$ [***]
	(ii)      On [***], upon the initial achievement of [***] (1)	US$ [***]
	(iii)     On [***], upon the initial achievement of [***] (1)	US$ [***]
	(iv)     On [***], upon the initial achievement of [***] (1)	US$ [***]
	(v)      On [***], upon the initial achievement of [***] (1)	US$ [***]

 

		(1)	If there is [***] and therefore no [***], the combined Net Sales of the Products (SYMJEPI and ZIMHI)
will then be counted toward the achievement of the above Commercial Milestones. For the avoidance of doubt, the cumulative Commercial
Milestone Payments shall not exceed a total of US$ [***].

 

     

     

    

 

SCHEDULE D

 

Products

 

“Product” or “Products”
means the Company’s injection product containing epinephrine in 0.3mg/0.3mL, 0.15mg/0.3mL, and any other strength, as approved
by the FDA under NDA number 207534, as amended, and/or any the Company’s injection product containing naloxone in 5mg/0.5
mL, and any other strength, pending FDA approval under NDA number 212854, as amended, in finished, packaged form that is distributed
by USWM under the Licensed Trademarks SYMJEPI and ZIMHI pursuant to their respective NDAs, in each case, in the Territory, under
USWM NDC numbers, pursuant to this Agreement.

 

     

     

    

 

SCHEDULE E

 

Supply Price

 

The Supply Price shall be [***] Company’s
actual cost for Product without any Company markup or allocation of Company overhead. The Supply Price shall include [***]. The
following is an estimate of Third Party costs under the current Product Manufacturer agreements.

 

SYMJEPI

 

Primary Assembly – the primary assembly,
which includes [***], will be conducted at [***]. Pursuant to the supply agreement, [***] sources all material and components required
to complete the primary assembly and [***] cost is determined by [***]. The approximate current cost of primary assembly at [***]
is [***] and [***] and [***] for batches of [***] and [***], respectively. The approximate direct cost of shipping the filled syringes
from [***] to [***] for [***] and [***] batches of [***] and [***], respectively.

 

Final Assembly – the final assembly,
which includes [***], will be performed at [***]. The cost of final assembly varies based on [***]

 

The estimated annual capacity for [***]
is [***]) doses and [***] is at least [***]) doses. Presently, the [***] dose is assembled on [***] and the [***] dose is assembled
on [***]; however, the Company, at its sole expense and cost (e.g., not to be included in the Supply Price), plans to [***].

 

By way of example, if a [***] unit batch
of SYMJEPI was assembled on the [***] when the forecasted combined annual volume was [***], the estimated total cost would be [***].

 

ZIMHI

 

Primary Assembly – the primary assembly,
which includes [***], will be conducted at [***]. The cost of primary assembly includes [***]. Pursuant to the supply agreement,
[***] will source all material (except API) and components required to complete the primary assembly and [***] cost will be determined
by [***]. The total cost of primary assembly, including [***] is estimated to be [***] and [***] per [***] for batches of [***]
and [***], respectively. The approximate direct cost of shipping [***] from [***] to [***] for final assembly is [***] and [***]
per syringe for batches of [***] and [***], respectively.

 

Final Assembly – the final assembly,
which includes [***], will also be performed at [***] and the cost of final assembly is [***]. [***] has been [***]; however, the
Company, at [***], plans to [***].

 

By way of example, [***] unit batch of
SYMJEPI was assembled on the [***] when the forecasted combined annual volume was [***], the estimated total cost would be [***].

 

Company shall maintain complete and accurate
written records of all costs relating to Product and will make these records available to USWM as requested in accordance with
this Agreement. During the Term, Company shall [***].

 

     

     

    

 

SCHEDULE F

 

Commercial Efforts and Sales and Distribution
Allocation

 

“Commercial Efforts”
as described in this Agreement shall mean the specific activities involved in USWM’s Commercial Efforts for each Product
and could [***]. More generally, such activities would include [***]: [***]. Commercial Efforts for a given Marketing Year would
include, but not be limited to, [***]:

 

		1)	[***];

 

		2)	[***];

 

		3)	[***]; and

 

		4)	[***].

 

The allocation of cost for these functions
via [***] would be determined [***] and would be [***].

 

Notwithstanding anything in this Agreement
to the contrary, USWM shall not be deemed to be in breach of its Commercial Efforts obligations under this Agreement so long as
USWM actually [***].

 

“Sales and Distribution Allocation”
as described in this Agreement shall mean [***] including, without limitation, (i) [***], (ii) [***], and (iii) [***].

 

The Parties acknowledge and agree that,
with respect to [***], commencing as of [***], the allocation of shared sales expenses will be allocated [***].

 

The Company shall have the right to reasonably
audit USWM’s Books and Records for purposes of verifying the Commercial Efforts and the calculation of the Sales and Distribution
Allocation under this Agreement (for purposes of clarity, any such audit described herein shall be limited to only include those
records of USWM that are applicable to/for verifying USWM’s Commercial Efforts performance and the calculation of the Sales
and Distribution Allocation pursuant to this Agreement). Such audits may be requested no more than [***] per [***] period during
the Term and once during the [***] period following [***]. Such audits shall be limited to USWM’s Books and Records which
are relevant for verifying the Commercial Efforts and/or the calculation of the Sales and Marketing Allocation, and for no earlier
than [***] immediately preceding such audit. Any such right to audit shall be exercised only on at least [***] advance written
notice.

 

     

     

    

 

SCHEDULE G

 

Approved Product Manufacturer

 

Catalent [***] located at [***]

 

[***]

 

[***]

 

[***]

 

     

     

    

 

SCHEDULE H

 

Licensed Trademarks Usage Guidelines

 

Pursuant to the Distribution
and Commercialization Agreement dated May 11, 2020, by and between Adamis Pharmaceuticals Corporation, a corporation organized
under the laws of Delaware, with an office located at 11682 El Camino Real, Suite #300, San Diego, CA 92130 (“Licensor”)
and USWM, LLC a limited liability company organized under the laws of Delaware, with an office at [***] (“Licensee”)
(the “Agreement”) and to create and maintain strong trademark protection, Licensee should follow these guidelines
when using any Licensed Trademarks in print and electronic materials. In the event a conflict arises between these Usage Guidelines
and the Agreement, the terms contained in these Usage Guidelines shall control with respect to matters relating to the usage of
the Licensed Trademarks. Any capitalized terms used but not defined herein shall have the meaning ascribed to them in the Agreement.

 

[***]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00313-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00313-of-00352.parquet"}]]